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Primary central nervous system (CNS) tumors (including brain and spinal cord tumors) are a 
heterogeneous group of neoplasms originating from intracranial tissues and the meninges with 
degrees of malignancy ranging from benign (non-malignant) to aggressive (malignant) (1-3). The 
focus of this thesis is on meningiomas, that represent about one third of all tumors of the CNS (4). 
The exact cause of meningiomas is not well understood; associations have been found with genetic 
(inherited), hormonal, and environmental factors (i.e., radiation exposure) (5). Incidence increases 
with age and reaches its peak in the sixth and seventh decades (6). Although meningiomas are the 
second largest group of symptomatic primary brain tumors, incidence, epidemiology, and clinical 
outcomes have generally been poorly defined (7). According to the Netherlands Cancer Registry, 
450 to 500 patients are diagnosed with a symptomatic meningioma each year (i.e., 1.8 per 100,000 
males and 4.5 per 100,000 females) (6). Meningiomas are by far the most common incidentally 
found brain tumors, with estimates in the literature ranging from 1% to 3% (6). In the Netherlands 
it is estimated that 75,000 to 100,000 individuals have such an asymptomatic meningioma (6).
Availability of magnetic resonance (MR) imaging has facilitated the detection and diagnosis 
of meningiomas (8). In addition, advances in neurosurgery, anesthesiology, radiotherapy and 
radiosurgery have led to reduced morbidity and mortality of treatment modalities, and to better 
survival rates (9). As a consequence, the individual patient’s quality of life and cognitive functioning 
are increasingly recognized as important parameters in clinical decision making.
MENINGOMA
Although meningiomas are often referred to as brain tumors, they actually arise from the meninges 
(more specifically, arachnoidal cells) and do not grow from brain tissue. Meningiomas typically 
present as slowly growing dural-based masses (10). They are classified into 3 grades according to 
the system of the World Health Organization (WHO) (11, 12). WHO grade I, or benign meningiomas, 
constitute approximately 90-95% of all meningiomas. These tumors grow slowly and have the most 
favorable long-term survival, although less than in the general population (12). A retrospective 
Dutch study found that 10- and 20-year survival in patients that were operated for a benign 
meningioma was respectively 81% and 53% (as compared to respectively 86% and 66% in the 
general population when corrected for age and sex) (6). Atypical meningiomas (grade II) and 
malignant meningiomas (grade III) comprise approximately 5-10% of the total, and these patients 
have a poorer prognosis than benign meningiomas (13). Atypical meningiomas refer to a more 
aggressively growing form of meningioma with brain invasion, that are more likely to recur after 
treatment (13). WHO grade III meningiomas, also named anaplastic or malignant meningiomas, 
form the smallest group. These tumors are highly invasive and often recur rapidly despite various 
treatments, making them cancers that are very difficult to control (6, 10). Overall survival is around 
5 years (13).
TREATMENT
Neurosurgical resection is often the first choice of treatment for symptomatic meningiomas, 
depending on the mass effect and location of the tumor as well as surgical risks, age and 
medical condition of the patient (14, 15). Benefits of surgery need to be balanced against those 
of radiosurgery or radiotherapy, and against a watchful waiting policy. Radiotherapy is mostly 
reserved for meningiomas that are inoperable, or where a significant remnant was left during 
surgery (16). Radiotherapy is also used for recurrent meningiomas or as adjuvant treatment 
in grade II or III meningiomas (15, 16). Radiosurgery (e.g., with a Gamma Knife) can be a good 
alternative for resection in case of smaller meningiomas (maximum diameter ± 3-4 cm), and is 
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able to stop tumor growth in a significant number of cases (i.e., control the disease) or even cause 
tumor shrinkage with improvement of symptoms (17).  
COGNITIVE FUNCTIONING IN PATIENTS WITH MENINGIOMA
Meningiomas can reach a considerable size before clinical symptoms appear, presumably due to 
their slow growth pattern and the plastic potential of the brain (i.e., the potential of the nervous 
system to reshape itself during ontogeny, learning or following injuries) (18-20). Depending on 
the size and location of the meningioma, patients may suffer from a wide variety of somatic and 
psychological symptoms. Common presenting symptoms are epileptic seizures, focal neurological 
deficits (ranging from visual disturbances to sensorimotor weakness), cognitive symptoms (e.g., 
memory problems, attentional problems), and psychiatric symptoms (e.g., anxiety, depression, 
psychosis) (21, 22). Symptoms are usually attributed to the local mass effect of the tumor, 
and are in some cases also explained by a general increase in intracranial pressure (22). The 
mechanisms through which cognitive deficits develop and progress, however, are incompletely 
understood. Several other causes may contribute to cognitive impairments, including tumor-
related epilepsy, medication (e.g., anti-epileptic drugs, steroids), and complications of treatment 
(e.g., stroke after surgery or side-effects of radiotherapy) (14, 23, 24). Anxiety and depression 
symptoms as emotional reactions to diagnosis and prognosis may also have a negative impact 
on cognitive functioning in meningioma patients (25). Finally, patients’ coping style can influence 
their emotional adjustment to diagnosis (26). 
Cognitive dysfunction is a common problem in patients with primary brain tumors (1). Most 
studies in this area have focused on patients with gliomas i.e., primary tumors arising from the 
glia cells in the brain (3). Remarkably, only very limited data is available on cognitive functioning 
in meningioma patients, compared to the quantity of data regarding clinical and oncological 
outcome measures in these patients (e.g., neurological status, rate of survival, tumor recurrence, 
and disease progression) (24). When I started this research project, in 2012, there were hardly any 
studies on cognitive functioning in meningiomas. Although meningiomas are extra-axial tumors 
(i.e., tumors that originate outside of the actual tissues of the brain), cognitive decline may arise 
due to edema and mass effect on normal cerebral tissue (24). This stresses the importance of this 
research project, especially since cognitive deficits in meningioma patients can be subtle and can 
go unnoticed during neurological examination. At the time I started the review of the literature 
there were 11 studies that evaluated cognitive functioning in meningioma patients before and after 
treatment (i.e., surgery with or without adjuvant radiotherapy). Only 6 of these 11 studies reported 
on cognitive performance as primary outcome measure. In general these studies indicated that 
meningioma patients have impaired cognitive functioning both before and after surgery. Deficits 
were observed in various cognitive domains including memory, attention, and executive function 
(27). Surgery generally seemed to have a beneficial effect on cognitive function. Although a 
significant improvement in cognitive functioning was found 3 to 9 months after surgery (mostly 
on memory, attention, and executive function), cognitive performance remained on average below 
normal (see Chapter 3 for an extensive review on cognitive functioning in meningioma patients). 
All these studies thus reported cognitive outcome measures in meningioma patients at group 
level. Group results, however, mask response variability among individuals, and are therefore of 
limited use in clinical practice.  
Taken together, there are many questions left regarding cognitive functioning in meningioma 
patients, both before and after surgery. It is largely unknown what factors determine individual 




patient will benefit (or not) from the procedure at the cognitive level. Answers to these questions 
are not only of interest from a scientific point of view, but will provide both clinician and patient 
with information that improves the quality of the decision-making process. For this purpose, 
we implemented routine cognitive testing in clinical practice for meningioma (and other 
neurosurgical) patients, both before and after surgery. As traditional neuropsychological testing 
generally takes several hours and is very labor-intensive, a brief neuropsychological assessment 
was therefore chosen. In recent years various computerized neuropsychological test batteries 
have been developed that offer an attractive alternative to the (often more lengthy) traditional 
neuropsychological paper-based assessment.
COMPUTERIZED COGNITIVE TESTING 
Computerized neuropsychological test (CNT) batteries have become increasingly popular in 
clinical and research settings over the past years (28). Major advantages of CNT’s include a shorter 
assessment time, lower costs of test administration, a more accurate measure of reaction time and 
less time-consuming scoring procedures (28, 29). Although current computerized testing programs 
are advantageous, they cannot yet fully replace the diagnostic work of a clinical neuropsychologist. 
For example, computers are unable to extract information gained from interaction and clinical 
observation, nor can they draw conclusions regarding the level of attention, motivation, or fatigue 
(30). However, computerized testing programs provide an adequate and time-efficient clinical 
technique to rapidly screen for possible cognitive deficits in patients, and are easier to implement 
in daily clinical care than traditional cognitive paper-and-pencil assessments (28). At the same 
time CNT’s are much more comprehensive than for example the Mini-Mental State Examination 
(MMSE). Also, computerized tests facilitate administration of alternative forms of a test (with 
numerous combinations of randomly presented test stimuli) which mitigate practice effects (28). 
They can quickly provide a fully automated calculation and presentation of the results (in terms 
of raw scores as well as standardized scores related to normative data), which can be included 
into summary reports automatically (28, 29). Therefore, such a screening instrument seems very 
promising for clinical purpose in meningioma patients.
One such computerized neuropsychological battery is the Central Nervous System Vital Signs 
(CNS VS (28)), which is a battery that has been translated into over 50 languages including Dutch 
(http://www.cnsvs.com). In contrast to other computerized batteries, for which new tests were 
developed, CNS VS is composed of tests which are mostly based on well-established conventional 
paper-and-pencil tests (28). CNS VS has been shown to be well suited for use as a brief clinical 
screening tool for cognitive dysfunction in different patient groups such as patients with mild 
cognitive impairment and dementia, post-concussion syndrome and severe traumatic brain 
injury, (treated and untreated) ADHD, and (treated and untreated) depression (28). It comprises 
7 neuropsychological tests, with measures of performance in 11 cognitive domains (i.e., composite 
memory, verbal memory, visual memory, psychomotor speed, reaction time, complex attention, 
cognitive flexibility, processing speed, executive function, simple attention, and motor speed). 
Since some domains scores generated by CNS VS are very similar and show considerable overlap 
with other domains of the battery (i.e., mainly calculated based on components of the same tests), 
not all 11 cognitive domains will be considered in this study. Administration lasts 30-40 minutes 
and the presentation of stimuli is randomized in order to minimize practice effects. Raw scores 
include total numbers of correct or incorrect responses, reflecting accuracy, and mean reaction 
times (in milliseconds) on individual tests and domains, reflecting speed. Normed scores are 
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automatically generated by CNS VS and represent the performance of an individual relative to 
the American normative sample corrected for age (N  = 1,069+ (28)).
The studies presented in this thesis employ CNS VS in order to evaluate cognitive functioning 
in patients with meningioma before and after surgery. Setting up this research project properly 
took a large amount of time and planning effort (e.g., approval by the medical ethical committee, 
embedding neuropsychological assessments before and after surgery within routine clinical care 
for meningioma patients, etc.). The department of Neurosurgery of the Elisabeth-TweeSteden 
Hospital (Tilburg, The Netherlands) together with the department of Cognitive Neuropsychology 
of Tilburg University has developed a protocol for computerized neuropsychological testing 
in which brain tumor patients admitted for surgical resection underwent neuropsychological 
assessment 1 day before surgery and 3 months after surgery as part of standard clinical neuro-
oncological care. A 12 months post-operative follow-up assessment was added later (January 
2014) for research purposes in order to explore long-term cognitive functioning. At the start of this 
research project, we evaluated the use of the CNS VS battery as a brief clinical tool for screening 
for cognitive dysfunction, as (the formal Dutch translation of) this tool had not been used before 
in a Dutch neurological patient sample. Patients suffering from trigeminal neuralgia (TN; a severe 
chronic facial pain disorder) were assessed with CNS VS (10) 1 day before surgical microvascular 
decompression (MVD; a procedure that requires a craniotomy and frees the root of the trigeminal 
nerve from compression of an artery). Thus, similar to brain tumor patients, patients suffering 
from TN undergo a craniotomy procedure under general anesthesia with the difference that MVD 
for TN does not require an operation into the brain tissue. Since the largest neurocenter of the 
Netherlands is located in the Elisabeth-TweeSteden Hospital, we had access to a relatively large 
group of these patients. In addition, no information was available on cognitive performance in TN 
patients as no prior studies had been conducted, which prompted us to start our research project 
with this particular patient group. 
AIMS AND OUTLINE OF THE THESIS
The aim of this thesis is to evaluate cognitive functioning in meningioma patients, and, more 
specifically to gain new insights in individual test performances and changes of performance after 
surgery. In addition, this thesis also aimed to evaluate computerized testing as a clinical instrument 
to detect cognitive impairment in meningioma patients. Chapter 2 presents a systematic review on 
cognitive functioning in meningioma patients. We evaluated relevant findings and methodologic 
aspects of studies on cognitive functioning in meningioma patients before and after surgery with 
or without adjuvant radiotherapy. In Chapter 3 we evaluated the first-time use of the formal 
Dutch translation of the CNS VS battery as computerized clinical neuropsychological screening 
tool for cognitive function in a (Dutch) neurological patient population (N = 32). In addition, this 
was the first study on cognitive function in patients with TN (N = 32). For the purpose of this study 
we compared patients’ cognitive performance with performance of 2 control groups of healthy 
subjects: the normative American data from the CNS VS database and a group of Dutch healthy 
individuals that we recruited ourselves, in order to evaluate the application of the normative data 
and also the formal translation in Dutch of CNS VS to the Dutch population. Chapter 4 reports on 
the clinical application of CNS VS in meningioma patients (N = 68). This was the first prospective 
study on cognitive function in patients with meningioma and it investigated the incidence and 
severity of cognitive dysfunction in 68 meningioma patients before and 3 months after surgery, 
and the change in dysfunction over time, both at group and individual patient level. All patients 




compared the normative data of CNS VS to a new large Dutch sample (N = 158), since the data of 
the CNS VS battery are based on the American population that were solely corrected for age and 
had also been collected over a decade ago. Chapter 6 describes individual changes in cognitive 
performance over time and predictors of late cognitive functioning in meningioma patients 12 
months after surgery by using socio-demographically adjusted normative formulae for the Dutch 
population, based on CNS VS resulting from the study described in Chapter 5. Finally, Chapter 7 
provides a summary and a general discussion. Methodological strengths and weaknesses of the 
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As a result of increasingly effective disease management, patients with brain tumors have better 
survival rates. This prompts a different approach towards health care. Instead of considering 
survival as the sole endpoint, quality of survival is also considered (1). The assessment of health 
related quality of life (HRQoL) and cognitive function has become increasingly recognized as an 
important outcome measure in brain tumor research. Cognitive functioning has a significant 
impact on HRQoL, and could even be a predictor of HRQoL (2).
To date, most studies on cognitive functioning in brain tumor patients have focused on glioma 
patients. Less is known about cognitive functioning in meningioma patients and the impact 
of surgery and/or (adjuvant) radiotherapy (3-10). Rapidly growing tumor types such as high-
grade gliomas typically lead to more cognitive impairment than slowly growing tumors such as 
meningiomas (11, 12). However, even meningiomas can cause cognitive deficits by putting pressure 
on brain tissue (13). These tumors often grow to a considerable size before clinical symptoms 
appear because of the plastic potential of the brain (14-17). 
The objective of this systematic review was to evaluate the available data and the quality of 
studies on cognitive impairment in meningioma patients prior to and/or following treatment, and 
to document potential changes in cognitive dysfunction due to treatment (i.e., surgery with or 
without adjuvant radiotherapy). We also reviewed methods used to evaluate cognitive function 
in meningioma patients, and make recommendations for future studies.
METHODOLOGY (SYSTEMATIC REVIEW)
Inclusion criteria
This systematic review included peer-reviewed research articles on cognitive functioning in adult 
patients with meningioma prior to and/or following surgery with or without adjuvant radiother-
apy, as assessed with neuropsychological tests.
Search strategy
Searches were conducted using the electronic databases of PubMed (MEDLINE) and Web of Sci-
ence (Web of Knowledge). For each database, searches included the terms: mening* or brain 
or cerebral or cranial (title/abstract, topic), in addition, an ‘and’ condition was specified for the 
following 2 groups of terms: (1) neuropsycholog* or cognit* or neurocognit* or attention* or 
memory or executive function* (title), (2) tumor* or tumour* or neoplasm* (title). Searches were 
limited to adult human-beings and peerreviewed original research papers written in English. In 
addition, results of studies that examined cognitive functioning in groups of brain tumor patients 
were also included if separate analyses were done for meningioma patient groups. Studies with-
out objective measures of cognitive function as assessed with neuropsychological tests were 
excluded. Studies that used very short screening tests, such as Mini-Mental State Examination 
(MMSE) and 3MS examination (modified MMSE) were included, but are only briefly discussed. 
There were no restrictions on publication dates, and the final searches were done in December 
2015.
Study selection process
In total, 2205 article citations (i.e., 873 in PubMed + 1332 in Web of Science) were found and 
downloaded into EndNote (18). These were scanned using EndNote for duplicates, and 1193 were 
deleted, yielding a final total of 1012 articles.
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Then, the titles of these articles were sifted to exclude all articles that did not meet the 
objectives of this review, which resulted in the removal of 886 articles. This first sift resulted in 
126 articles for which abstracts and/or full text articles were assessed in detail. Subsequently, 
115 (out of 126) articles were rejected because they did not meet the inclusion criteria, were 
conference presentations or case reports. The remaining 11 articles were examined jointly by 2 
reviewers and remained included for this review.
RESULTS
Table 1 summarizes the 11 studies that evaluated cognitive functioning in meningioma patients 
prior to and/or following treatment. In this section, results from studies including pre-operative 
and post-operative cognitive assessments are discussed. The effects of adjuvant radiotherapy 
on cognitive outcomes are discussed in a subsequent section. Potential associations of cognitive 
impairment with tumor location and other factors are presented in Box 1. 
Cognitive functioning in meningioma patients prior to and/or following surgery
Cognitive functioning prior to treatment was examined in 5 studies with a total of 199 meningioma 
patients eligible for surgery (4, 7, 10, 19, 20) (see Table 1). Overall, in these studies, cognitive 
functioning has been found impaired. Most commonly affected domains were memory, attention, 
and executive functions. Cognitive functioning following surgery was investigated in 7 studies 
including a total of 302 meningioma patients (4, 7-10, 19, 20) (see Table 1). All studies, except 2 
(8, 9), started with a pre-operative assessment. Pre-operative assessments allow to determine 
possible effects of surgery on cognitive performance. Only 2 (4, 20) of the 5 studies with a repeated 
(pre-and post-operative) assessment of cognitive function controlled for the influence of practice 
effects. In general, all studies showed significant improvements following surgery in cognitive 
functioning, mostly on memory, attention, and executive function. There was no consistency in 
results across studies with regard to the cognitive domains that did not improve after surgery. 
However, despite cognitive improvements, all studies (including those without pre-operative 
assessment) demonstrated that patients (still) had significantly lower scores on various cognitive 
domains after surgery, compared to healthy controls. For studies including a pre-and post-
operative assessment (mean interval between 2 assessments ranging from 3 to 9 months), no 
clear conclusions can be drawn on the effect of time since surgery on the post-operative cognitive 
outcome. Severity data (e.g., effect sizes, incidences) were not available for most of them, due 
to differing populations.
In particular, Tucha and colleagues (4) found significant pre-operative impairments in patients 
with frontal meningiomas (N = 54) on measures of working memory, attention, and executive 
functions (lower mean raw scores, longer reaction times, or higher error rates), compared to 
healthy controls (matched for age, gender, educational level, handedness, and intelligence). After 
surgery, significant improvements were observed on measures of memory and attention. However, 
despite these significant improvements, patients’ post-operative status remained significantly 
impaired on attention and executive functions, compared to healthy controls who were retested 
over the same intervals. According to the authors, only the better post-operative performance on 
figural memory (immediate recall) could be partly explained by practice effects by comparing the 
test results with the healthy control group. Note that the authors classified flexibility and shifting 
as subdomains of attention. However, these measures can also be considered as components of 
executive functioning (21). In addition, Tucha and colleagues (10) conducted a study with elderly 




measures of working memory, short-term figural memory, attention, and executive functions 
(lower mean raw scores, longer reaction times, or higher error rates), compared to healthy controls 
in the same age-range. After surgery, significant improvements were observed on measures of 
memory and attention, with the exception of working memory. In this study, patients’ post-
operative cognitive status corresponded with the cognitive functioning of the healthy control 
group  (except for working memory). Because the healthy controls were only tested once, it was 
not possible to rule out practice effects, which may have masked lower performance in the elderly 
meningioma patients. See the above-mentioned note regarding the classification of cognitive 
domains by these authors. It was not reported if there was overlap in patients between these 2 
studies by Tucha and colleagues; a certain amount of overlap between the patient samples seems 
possible (4, 10). 
In a recent study by Meskal and colleagues (20), meningioma patients (N = 68) had significantly 
lower mean pre-operative and post-operative standard scores on measures of memory, 
psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, and 
executive functioning, compared to (American) normative data as provided by the Central Nervous 
System Vital Signs battery (i.e. CNS VS), a brief (30 min) computerized battery of neuropsychological 
tests (22). Forty-seven out of 68 patients (69%) scored low or very low on 1 or more cognitive 
domains. After surgery, significant improvements were observed on all cognitive domains, with 
the exception of psychomotor speed and reaction time. Twenty-seven out of 62 patients (47%), 
scored low or very low on 1 or more cognitive domains after surgery. 
The 3MS test used in a study by Yoshii and colleagues (7) showed a subnormal function (mean 
3MS score < 85) in 34 meningioma patients pre-operatively. Cognitive function normalized after 
surgery only in patients with right-sided (N = 17) meningioma (post-surgery mean 3MS score 
> 85). Note that the authors have chosen for a more stringent cut-off of 85 instead of 77/78, 
which is generally used as cut-off for cognitive impairment (23). In addition, patients were tested 
within 1 month after surgery, which is a very short follow-up time that may identify (more severe) 
transitory cognitive problems instead of persistent cognitive deficits in left-sided meningioma 
patients. Furthermore, it was not clearly described by the authors why some patients had only 1 
assessment (i.e., prior to, or following surgery), and other patients were assessed twice with the 
3MS test (prior to, and following surgery).
Another study, by Koizumi and colleagues (19), evaluated cognitive dysfunction with the MMSE 
in meningioma patients (N = 10) who also underwent 123I-Iomazenil (IMZ) single-photon emission 
computed tomography (SPECT) imaging. The mean pre-operative MMSE scores were 19.9 ± 11.4; 
ranging from 2 to 30. The MMSE cutoff points for normal, mild, moderate, and severe cognitive 
impairment were not described by the authors. Based on the MSSE cut-off levels application by 
Folstein and colleagues (24), 3 patients had moderate to mild cognitive impairment (scores on 
MMSE ranging from 20 to 25), and 3 patients had severe cognitive impairment (scores ranging 
from 2 to 5); 4 of them had scores of 29–30. Overall, 6 patients scored above the cut-off point of 
23. After surgery, a significant improvement in cognitive function (mean post-surgery MMSE: 26.5 
± 3.8) was found. Seven of the 10 patients scored above the cut-off of 23 on the MMSE, which 
suggests ‘normal’ cognitive functioning in those patients. Note that screening tests such as the 
MMSE and 3MS are not sensitive enough to discriminate between mild cognitive impairment and 
normal cognitive functioning (25).
Van Nieuwenhuizen and colleagues (6) found significantly lower mean Z-scores in patients with 
a wait-and scan policy = 21) on measures of psychomotor speed and working memory, compared 
to normative matched healthy controls from the Maastricht Aging Study (i.e., MAAS (26)). Note 
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that this study was conducted in a specific group of meningioma patients, in which the tumor 
was small, growing slowly, and was not causing symptoms or if surgery carried too many risks, 
particular for older patients who are more vulnerable to develop complications after surgery due 
to their medical condition.
Steinvorth and colleagues (27) included 10 patients admitted only for fractioned stereotactic 
radiotherapy (FSRT) instead of surgery. However, the authors did not report cognitive results. 
Note that the patients who were included in the studies by Van Nieuwenhuizen and colleagues 
(6) and Steinvorth and colleagues (27) were substantially different (e.g., smaller tumor volumes, 
inoperable meningiomas after subtotal resection or recurrence) from those patients who were 
admitted for surgical treatment. Therefore, the results of the aforementioned 2 studies cannot 
be generalized to the general population of meningioma patients admitted for surgery.
In another study by Van Nieuwenhuizen and colleagues (8) in which some (N = 18) meningioma 
patients were tested only after surgery and not before, significantly lower mean standard scores 
were found on a number of verbal memory subtests, compared to normative healthy controls. The 
authors concluded that these patients had significantly lower cognitive functioning than healthy 
controls. Attention and executive function were not impaired in these patients. The patients of 
this study were compared with patients (N = 18) who received adjuvant radiotherapy after surgery 
(RTx+). The results of the latter patient group are discussed in the section on effects of adjuvant 
radiotherapy. It should be noted that although overlap in patients between this study and the 
above-mentioned study of Van Nieuwenhuizen cannot be ruled out, this is not likely since the 
study in patients who had already undergone surgery (8) preceded the study in patients in whom 
surgery was not performed (6).
Similar to the aforementioned study, Krupp and colleagues (9) investigated cognitive 
functioning after surgery without a pre-operative assessment in 91 patients. Compared with 
published normative population values, major deficits in attention appeared in patients of 
approximately 55 years of age, worsening in patients with increasing age. Significant negative 
correlations were found between age and attention performance in patients older than 55, as 
well as with the intelligence factors verbal knowledge, technical ability, and word fluency. No such 
correlation was found for reasoning and age. Since no pre-treatment assessment was available 
in the aforementioned 2 studies, the specific effects of the brain tumor or surgery on cognitive 
performance cannot be determined.
Cognitive functioning in meningioma patients: effects of adjuvant radiotherapy
Three studies investigated cognitive functioning in meningioma patients who had undergone 
radiotherapy after surgery (2, 5, 8). These studies described the same (2, 5). or an overlapping (8) 
patient sample, but investigated different types of research questions. In these studies, patients 
in whom the tumor could only be partially resected and patients with a recurrence after surgery 
received adjuvant radiotherapy. 
The study by Van Nieuwenhuizen and colleagues (8) investigated the exclusive effects of 
adjuvant radiotherapy after surgery by comparing patients who had surgery only (RTx-) with 
patients who had surgery and adjuvant radiotherapy (RTx+). The authors found no significant 
differences in mean standard scores on all cognitive measures (memory, attention, executive 
function, and perception) between RTx- (N = 18) and RTx+ (N = 18) patients (which may be patients 
with different tumor characteristics). No comparisons were made for cognitive functioning between 
the RTx+ group and healthy controls. In this study, additional radiotherapy did not have deleterious 




colleagues (2) did not differentiate between the effects of surgery and/or radiotherapy. In the 
study by Dijkstra and colleagues, patients (N = 89) showed significantly lower mean Z-scores 
on measures of verbal memory, visual memory, working memory, information processing, 
psychomotor speed, and executive function (most impaired), compared to normative matched 
healthy controls (from MAAS (26)). No significant differences were found for attention. Note that 
the proportions of patients with cognitive deficits (defined as 1.5 SD below the mean of a matched 
control group) was not reported by these authors. The study by Waagemans and colleagues (2) 
focused on HRQoL and reported similar findings on cognitive functioning in meningioma patients 
(N = 89) as in the study by Dijkstra and colleagues (5). A common limitation of the aforementioned 
studies was an absence of a pre-treatment assessment of cognitive functioning. Also noteworthy 
is the large standard deviation (SD) of tumor volumes in these studies.
Only 1 study (27) investigated the effects of FSRT following surgery in meningioma patients 
(N = 30). In this study, cognitive function was evaluated before and after FSRT. Patients had normal 
mean percentile scores, except for a slow information processing speed prior to radiotherapy. 
After the first fraction, a transient decline in memory and, at the same time, improvements in 
attentional functions were observed. No deteriorations were seen during the further follow-up, 
but further increases in memory and attention were observed. Note that the improvement in 
attention was considered as a practice effect, since a comparable improvement was also observed 
in a control group, included in an earlier report by these authors (27).
21

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Relevant findings Study 
Tumor 
location 
.No sign differences in cognitive status between lateralization groups prior 
to and following surgery. 
.Sign differences in changes over time between lateralization groups, 
mainly on attentional functions. Left-sided (N = 22) MGM improved sign on 
flexibility and shifting. Right-sided (N = 21) MGM improved sign on variety 
of attentional functions.
.Sign effect of frontal MGM on pre-operative and post-operative cognitive 
status. Prior to surgery; falx cerebri (N = 14) performed sign better on figural 
fluency than frontobasal (N = 19) and convexity (N = 17) MGM. Following 
surgery; frontobasal (N = 19) and falx cerebri (N = 14) MGM performed 
sign better on divided attention and figural memory than convexity (N = 17) 
MGM.  
.Sign differences between localization groups for various cognitive domains. 
Convexity (N = 17) MGM: only improvement on flexibility and shifting 
(attentional/executive functions), frontobasal (N = 19) MGM: improvement 
on a broader range of attentional/executive functions after surgery. Pts with 
falx cerebri (N = 14) MGM improved on various cognitive domains.
.No sign differences in cognitive status between lateralization groups prior 
to and following surgery. 
.No sign associations between tumor lateralization and cognitive 
improvement over time.
.No sign differences in pre-operative or post-operative cognitive functioning 
based on tumor localization, except for complex attention: sign better 
performance for infratentorial (N = 7) as opposed to supratentorial (N = 61) 
tumors. 
.No sign associations between tumor localization (skull base, convexity, and 
convexity/falx) and cognitive improvement over time. 
.Cognitive function normalized in right-sided (N = 17) MGM following 
surgery. Left-sided (N = 17) MGM did not normalize or improve. 
.No statistical tests were conducted in this study: no clear conclusions can 
be drawn.  
.No reports on specific localization or lateralization effects on cognitive 
functioning. 
.Based on data in a table; 3 pts with very low scores (<10) on MMSE 
before surgery, suffered from convexity (N = 4) MGM. These pts improved 
substantially after surgery, but still had the lowest scores on MMSE (≤ 23), 
compared with other localization groups. 
.No clear associations of memory functions with localization before FSRT 
(no data reported).
.No clear lateralization effects before and after FSRT. 
.Pts with left-sided (N = 37) MGM performed sign worse on verbal memory 
compared to right-sided (N = 25) MGM. 
.Lower cognitive performance in skull-base (N = 24) MGM on verbal memory, 
information processing, and psychomotor speed compared to convexity 
(N = 28) MGM. Not clear as to whether theses analyses were done in smaller 
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Relevant 
factors
Relevant findings Study 
Epilepsy .Sign negative correlation between epilepsy burden and executive 
functioning, primarily due to AEDs use, not to epileptic seizures.
.Sign impaired cognitive functioning also in pts who did not use AEDs (N = 66) 
compared with HC. 
 .Comparable HRQoL in pts to that in HC. 
.HRQoL worse in pts with cognitive deficits and pts who use AEDs, 





Mood .No sign correlation between anxiety and cognitive domains, negative 
correlation between depression and 6/7 cognitive domains prior to surgery 
(N = 60 out of 68). 
.Negative correlation between anxiety and attention, negative correlation 
between depression, memory and attention following surgery (N = 52 out 
of 62).
.Sign improvement toward a positive mood from baseline (no data reported) 







.RT+ pts lower HRQoL than RT- pts. 
.No sign differences in HRQoL between RT- pts and HC. After correction 
for duration of disease, no sign differences in HRQoL between both MGM 
groups.  
.No comparisons were made for HRQoL between RT+ pts and HC.
.No sign differences between pts and HC on 7/8 HRQoL scales. 
.Impaired executive functioning had a direct negative relationship with other 
cognitive domains (information processing, verbal memory, psychomotor 












Abbreviations: AEDs=anti-epileptic drugs. FSRT=fractioned stereotactic radiotherapy. HC=healthy controls. 
HRQoL=health-related quality of life. IZM-SPECT=123I-iomazenil (IMZ) single-photon emission computed 
tomography (SPECT) imaging. MGM=meningioma. MMSE=mini-mental state examination. Pts=patients. 
RT=radiotherapy. Sign=significant. 





This systematic review provides an overview of studies investigating cognitive functioning in 
meningioma patients prior to and/or following surgery with or without adjuvant radiotherapy. 
Drawing conclusions from studies and comparison of results between them were complicated 
by several methodological limitations, such as a lack of pre-treatment assessments, variations 
in the number and types of neuropsychological tests used, definitions of cognitive impairment, 
quality of normative data, and absence of control for practice effects.
Specific effects of treatment cannot be determined in the absence of an assessment before 
treatment. The number of patients with above average cognitive abilities before treatment may 
be underestimated. Patients may have a functional decline, but still perform within normal ranges 
on cognitive tests. In addition, cognitive deficits that have been present before treatment may 
be unjustly attributed to surgery. None of the studies described the presenting symptoms of the 
meningioma patients included. Therefore, it is not clear if cognitive complaints were present at 
neuropsychological assessment. As the cognitive status of patients with incidentally-detected 
meningiomas is likely to differ from that in patients presenting with cognitive complaints, it is not 
clear as to whether the samples were representative of all meningioma patients.
In addition, the number and types of neuropsychological tests used, varied across studies and 
complicated comparison of results. For example, 8 studies (2, 4-6, 8-10, 27) tested patients with a 
traditional neuropsychological battery that consisted of 2 to 12 paper-and-pencil tests. One study 
used a computerized screening battery (i.e., CNS VS (22)) consisting of 7 neuropsychological tests 
(20). Two studies (7, 19) used very global screening tests (i.e., MMSE and 3MS), that are known 
to have a low sensitivity and are not useful for screening for subtle cognitive impairment (25).
Quality of normative data also differed between studies, 2 studies included their own healthy 
control group matched on different variables  (4, 10), 4 studies used normative matched data 
from 18 to 89 healthy controls from the Maastricht Aging Study (MAAS (26)) (2, 5, 6, 8), and 5 
studies used (published) normative healthy population values as provided by the test (manual) 
(7, 9, 19, 20, 27).
Further, definitions used to classify patients as having cognitive impairment differed across 
studies. Three studies (2, 5, 6) used Z-scores and defined individual cognitive impairment as 1.5 
SD below the mean of a matched control group. One study (20) defined standard scores of 1.5 
and 2 SD below the mean of a normative control group as cognitive impairment. Five studies (4, 
8-10, 27) did not use a definition of individual cognitive impairment. None of the studies reported 
a cut-off for (general) cognitive impairment on the number of tests required to be in an impaired 
range. Only 1 study (20) reported on the incidence and severity of cognitive impairment.
Finally, only 2 (4, 20) of the 5 studies with a pre-and post-treatment assessment considered the 
influence of practice effects on improved cognitive function after repeated testing by including a 
(matched) control group that was tested twice with the same test battery. The computerized test 
battery CNS VS is assumed to be suitable for repeated testing because of the random presentation 
of stimuli (20, 22). However, despite the chance that a patient gets the same stimuli twice is 
negligible, there still could be a learning effect of the battery in general, also known as test-
wiseness (28). The patient knows what to expect the second time. Thus, longitudinal studies 
without consideration of practice effects may report better results due to repeated exposure to 
neuropsychological testing. Practice effects may therefore mask cognitive decline or stability.
Moreover, many studies reviewed here lacked a clear description of statistical testing, or 
only very basic statistical analyses were conducted. For example, some studies only performed 
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univariate analyses where no correction for potential other differences between groups was 
applied when comparing effects of tumor localization (among groups).
To overcome some of the methodological issues described, we recommend using a test battery 
with a wide range of neuropsychological tests that is sensitive enough for identifying subtle 
cognitive impairment in patients and suitable for serial repetition. In addition, a pre-treatment 
assessment, a sufficiently large sample size to conduct (multivariate) analyses, a uniform definition 
of cognitive impairment, and appropriate quality of normative data are suggested.
Despite these limitations, the studies in this review demonstrate that meningioma patients 
have impaired cognitive functioning prior to treatment. In general, most commonly affected 
domains were memory, attention, and executive functions. Surgery generally had a beneficial 
effect on cognitive function. A significant improvement in cognitive functioning was found 3 to 
9 months following surgery, mostly on memory, attention, and executive function. Cognitive 
performance still remained below normal however. There is no consistency across studies about 
the domains that did not improve after surgery. In the one study on adjuvant radiotherapy, no 
additional deleterious effects on cognitive functioning at least 1 year after surgery were found. 
Two other studies found that the use of AEDs negatively affects cognitive functioning and HRQoL.
Mixed findings were reported with respect to effects of lateralization and localization of the 
tumor on cognitive impairment. In most studies, associations between cognitive functioning and 
other tumor characteristics (i.e., volume, edema) were not observed (2, 4, 5) or could not be 
made because of the small sample sizes in the studies (6). Other factors that are known to have 
a relation to cognitive performance prior to and/or following treatment, such as epilepsy, mood, 
and HRQoL were not systematically investigated across studies.
There is evidence to conclude that meningioma patients are faced with cognitive dysfunction 
in several cognitive domains before and (slightly less) after treatment. Clinicians should be aware 
of these deficits. Researchers should employ more rigorous methodologies. Better awareness, 
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Cognitive impairments can often be found in patients with chronic pain disorders, in particular 
when attentional capacity, processing speed, or psychomotor speed are measured (1-3). These 
impairments have been shown to affect therapy adherence, personal relationships, daily 
functioning, capacity for work, leisure activities, mood, and quality of life (4, 5). Surprisingly, no 
prior studies have investigated cognitive functioning in patients with trigeminal neuralgia (TN). 
In particular, the subset of patients that are candidates for surgical microvascular decompression 
(MVD; a procedure that requires a craniotomy and frees the root of the trigeminal nerve from 
compression of an artery) seem at high risk for cognitive impairments, because of severe, long-
standing and medically intractable pain. 
In recent years various computerized neuropsychological test batteries such as the Central 
Nervous System Vital Signs (CNS VS) have been developed that offer an attractive alternative to 
(often more lengthy) traditional neuropsychological paper-based assessment. 
In this study we evaluated the first-time use of the CNS VS battery as computerized clinical 
neuropsychological screening tool for cognitive dysfunction in patients with TN. The formal Dutch 
translation of CNS VS had not been used before in a Dutch neurological patient sample. A large 
group of patients with TN undergo neurosurgery in our hospital. Cognitive performance in these 
patients had not been studied before. We examined cognitive performance on these computerized 
tests in patients with TN before MVD in comparison with healthy controls.
PATIENTS AND METHODS
Patient population
Cases eligible for the current analyses were patients diagnosed with TN who were scheduled 
to undergo MVD between December 2010 and December 2012 at the Elisabeth-TweeSteden 
Hospital (Tilburg, the Netherlands). Exclusion criteria were: age under 18, history of intracranial 
neurosurgery, history of psychiatric or neurological disorders, history of cranial radiotherapy, 
lack of basic proficiency in Dutch and total unfamiliarity with the use of computers. Patients who 
were unable to undergo the neuropsychological test battery due to severe cognitive problems 
were additionally excluded. 
Healthy controls
Patients were compared with data from 2 control groups of healthy subjects: a normative American 
control group (N = 1,069) from the CNS VS database (6), and a Dutch control group (N = 20) who 
was recruited from the general population. 
CNS VS has a normative database from 1,069 subjects ranging in age from 7 to 90, drawn 
from the American population. In most age groups, there is a female predominance, ranging 
from 43% to 72%. Information about education of the American sample is not provided (6). Also 
no information was available from any of CNS VS’ analyses regarding the establishment of the 
battery’s normative data. It database comprises individuals who are in good health with no current 
or past psychiatric, neurologic, or cognitive disorder, and no current medication use. 
To be included in our own control group, a subject had to be free of pain and 
sociodemographically comparable to the group of patients with TN. Participants were considered 
healthy if (a) there was no past or present psychiatric or neurologic disorder; (b) they had no other 
major medical illnesses in the past year prior to participation (e.g., cancer, myocard infarct); (c) they 
were free of use of any centrally acting psychotropic medication; and (d) did not have a history 
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of or current alcohol or drug abuse. Dutch healthy controls were group-wise matched during 
recruitment to the patient group according to age, gender, and educational level. 
Procedure
One day before surgery, patients were hospitalized and tested. All patients were assessed with 
a standardized computerized neuropsychological test battery CNS VS (6). Test sessions were 
performed as part of the usual care in the Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands. 
Education was classified according to the coding system of Verhage ranging from 1 (only primary 
school) to 7 (university) (7). Patients also filled out the Dutch translation of the Hospital Anxiety 
and Depression Scale (HADS) (11). Socio-demographic information was collected by means of a 
checklist and interview. Clinical information was obtained from the electronic medical charts. 
Dutch healthy controls were also assessed with CNS VS. The computerized neuropsychological 
tests were, depending on participants’ preference, administered individually at Tilburg University 
(Tilburg, The Netherlands), Elisabeth-TweeSteden Hospital (Tilburg, The Netherlands), or at 
participants’ homes. Well-trained test technicians ensured appropriate conditions and remained 
present during the entire assessment. Participants filled out a questionnaire on health status.
Instruments
Cognitive functioning was assessed with the CNS VS battery, which consists of 7 tests (Table 
1) (6). The pencil and paper versions on which these tests are based are widely used by 
neuropsychologists. CNS VS has a normative database from 1,069 normal subjects ranging from 
age 8 to 90, drawn from the American population. Testing results are presented in subject (raw) 
scores, age-matched standard scores, and percentile ranks. CNS VS standard scores have a mean 
of 100 and a standard deviation of 15; higher scores indicate better performance. CNS VS has an 
official Dutch translation. The time needed to complete the battery is short, approximately 30–40 
min (6). For the purpose of this study, patients were evaluated on 5 cognitive domains (composite 
memory, psychomotor speed, reaction time, complex attention, and cognitive flexibility). We 
refer to complex attention and cognitive flexibility as measures of executive functioning. For a 
detailed description of the calculations of the domain scores, we suggest visiting the link http://
www.cnsvs.com.
Anxiety and depression were assessed with a Dutch translation of the Hospital Anxiety and 
Depression Scale (HADS) (11). This self-report screening instrument consists of 14-items: each 
subscale (i.e., anxiety and depression) includes 7 items with response options ranging from 0-3, 





Table 1 CNS Vital Signs description of clinical domains and tests (6)
Domains Tests Description 
Memory Verbal memory test
Visual memory test
Learning a list of 15 words, with an immediate 
recognition, and after 6 more tests a delayed 
recognition trial
Learning a list of 15 geometric figures, with an 
immediate recognition, and after 5 more tests a 
delayed recognition trial
Psychomotor speed Finger tapping
Symbol digit coding
Pressing the space bar with the right and left 
index finger as many times in 10 seconds
Above-mentioned
Reaction time Stroop test In the first part, pressing the space bar as soon 
as the words RED, YELLOW, BLUE, and GREEN 
appear
In the second part, pressing the space bar as 
soon as the color of the word matches what the 
word says
In the third part, pressing the space bar as soon 
as the word does not match what the word says
Complex attention Continuous performance test
Shifting attention task
Stroop test









Since no information was available from any of CNS VS’ analyses regarding the establishment of the 
battery’s normative data, standard scores (i.e., scores normalized and corrected for age by CNS VS) 
were used in the comparative analyses between the American sample and patients with TN. Raw 
scores were used in the comparative analyses between the Dutch sample and patients with TN. 
We performed several one-sample T-tests to explore whether TN patients differed from the 
normative sample (N = 1,069; M = 100, SD = 15 (6)) in cognitive test performance. To determine 
whether there was a differences in test performance between patients and the Dutch sample 
(N = 20), several independent-samples T-tests were used.
In addition, to gain insight in individual test performances, the number of patients scoring 1.5 
SD below average was counted for each of the 5 cognitive domains.  
A series of Pearson product-moment correlation coefficients was calculated to examine the 
potential relationship of anxiety and depression with cognitive performance.
Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) 
version 24.0. 
RESULTS
Demographic and clinical characteristics
Of the 43 patients scheduled for MVD, 11 patients were excluded from participation: 2 patients 
had a current neurological and psychiatric disorder, respectively multiple sclerosis (MS) and 
depression; 8 patients had previous MVD. In addition, 1 patient was excluded from further analysis 
because the test was interrupted due to severe facial pain. The final patient group consisted of 32 
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eligible patients (14 females, 18 males, M age = 54, age range: 24-74). The Dutch sample comprised 
20 healthy subjects (11 females, 9 males, M age = 50, age range: 22-80 years). The patients and 
healthy controls were comparable with respect to age, gender and educational level (Table 2). 










Age (mean ± SD)
Male/Female (n/n)
Highest level of education (mean; range) a
Use of AEDs, n (%) b
Anxiety pre-operatively mean (SD)
Depression pre-operatively mean (SD)




5.71 ± 3.16 c
4.72 ± 3.19 d






t =  1.17






a Education was classified according to the coding system of Verhage ranging from 1 (only primary school) 
to 7 (university) (7)
b Data on use of AEDs was available in 30 of the 32 patients due to missing reports 
c Data on pre-operative levels of anxiety and depression was available in 28 of the 32 patients
d Data on post-operative levels of anxiety and depression was available in 28 of the 32 patients 
NA = not applicable 
* p < .05
Test performance of TN patients in comparison with the American normative sample
Significant differences were found in mean standard scores between patients and the American 
normative sample on measures of composite memory, psychomotor speed, reaction time, complex 
attention, and cognitive flexibility, with patients performing worse than CNS VS’ normative sample 
(Table 3). 
Table 3 Comparison of means of the patient group (N = 32) compared with the normative sample





















a CNS VS standard scores have a mean of 100 and a standard deviation of 15; higher scores indicate better 
performance
* p < .05
Test performance of TN patients in comparison with the Dutch sample
Significant differences were found in mean raw scores between patients and the Dutch sample on 
measures of composite memory, psychomotor speed, complex attention, and cognitive flexibility, 
with patients performing worse than the Dutch control group. No significant differences were 




Table 4 Comparison of means of the patient group (N = 32) compared with the Dutch sample (N = 20)
Variables Patients
Mean ± SD a
Dutch sample
Mean ± SD a






90.78  ± 7.36
141.53  ± 32.01
719.09  ± 135.68
13.78  ± 11.84




6.80  ± 5.28











a Raw scores; ˆ higher score = better performance; ˇ lower score = better performance
* p < .05
Individual test performance of patients with TN
We found that 35% (highest proportion) of our patients had deficits on psychomotor speed, 32% on 
reaction time, 25% on complex attention and cognitive flexibility, and 19% on composite memory 
and processing speed (data not shown). 
Anxiety and depression
With regard to anxiety and depression scores there was no significant correlation with any of the 
cognitive domains (p > .05; data not shown). 
DISCUSSION
In this study we evaluated the first-time use of the formal Dutch translation of the CNS VS battery 
as computerized clinical neuropsychological screening tool for cognitive function in a (Dutch) 
neurological patient population. This was the first study on cognitive function in patients with TN. 
Cognitive dysfunction was examined with CNS VS before MVD and compared to healthy controls. 
For the purpose of this study we compared patients’ cognitive performance with performance 
of 2 control groups of healthy subjects: the normative American data from the CNS VS database 
and a group of Dutch healthy individuals that we recruited ourselves. 
In line with previous data of patients with other chronic pain conditions, we observed 
impairments in composite memory, psychomotor speed, reaction time, complex attention, 
and cognitive flexibility. Patients with TN performed significantly worse in comparison with the 
American normative sample on all of the 5 selected cognitive functions. Comparisons of patients 
with TN with our Dutch control group of healthy subjects revealed quite the same pattern of 
differences in mean test performance (i.e., composite memory, psychomotor speed, complex 
attention, and cognitive flexibility), with the exception of reaction time where no mean group 
difference was found. These results suggest that the American norms of the CNS VS database are 
applicable to our group of Dutch patients. Previous findings showed impaired executive function 
in chronic pain syndromes, which suggested that the frontal brain regions that control executive 
function may be the same as those involved in pain processing (9 - 11). In our study we also found 
deficits in the domains of memory, psychomotor speed, and reaction time. 
Evaluation of individual test performances, showed that 35% (highest proportion) of our 
patients had deficits on psychomotor speed, 32% on reaction time, 25% on complex attention 
and cognitive flexibility, and 19% on composite memory and processing speed. These results 
indicate that cognitive deficits can be objectified by CNS VS and that substantive proportions of 
patients with TN have cognitive deficits. 
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The present study is the first study that explored cognitive functioning with the computerized 
neuropsychological test battery (i.e., CNS VS) in Dutch patients who suffer from TN. However, this 
study has a few limitations. Firstly, the size of the patient sample in this study is small. Therefore, 
the results should be interpreted with caution and findings should be replicated in larger patient 
samples to compare the results. A second limitation is that our data concern a specific group of 
patients that was cognitively tested one day before MVD. Waiting for surgery is often accompanied 
with high levels of anxiety, which are known to affect cognitive functioning negatively (12, 13, 
14). However, there was no statistically significant correlation between pre-operative anxiety and 
pre-operative cognitive functioning. A third limitation is that the results are possibly confounded 
by the fact that the majority of TN patients were on anti-convulsant medication or opioids. It 
is well known that these drugs can interfere with cognitive functions (15-18). We are therefore 
unable to answer the question as to what the precise cause or causes of cognitive impairments 
in TN patients is or are. Clearly, follow-up research is needed to study the possible contribution 
of drug side effects.
Despite these methodological limitations, we can conclude that TN patients are at risk for 
cognitive deficits, and that clinicians should be aware of this risk and the subsequent negative 
impact on socioprofessional life. As mild or moderate cognitive impairments may not be detected 
with routine medical examinations, we propose that TN patients are routinely evaluated with 
neuropsychological testing (19). For this purpose, a brief computerized neuropsychological 
screening instrument can be a practical alternative to traditional neuropsychological testing that 
takes several hours. As MVD generally provides pain relief in many TN patients, and medication 
can frequently be tapered off after surgery, we hypothesize that MVD is a means to improve 
cognitive impairments. Future studies will help to better define the impact of other (psychological 
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CHAPTER   4
Cognitive improvement in meningioma patients after  
surgery: clinical relevance of computerized testing
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Cognitive dysfunction is common in patients with a primary tumor (1). Most studies have focused 
on glioma patients. However, less is known about cognitive functioning in meningioma patients 
and the impact of surgical treatment (2-9). In most of the studies that did focus on meningioma 
patients, cognitive functioning was not systematically assessed pre-operatively (4, 7, 8). In 2003 
Tucha and colleagues examined 54 patients with frontal meningiomas before and after surgery(3). 
They found that in comparison with healthy controls, meningioma patients showed significant 
pre-operative impairments on working memory, fluency functions, tonic alertness, processing 
speed, shifting, divided attention, and flexibility. Post-operatively, patients’ scores were again 
lower than the scores of healthy controls, although an improvement of attentional functions and 
no deterioration of overall cognitive functioning was observed.
This is the first study in which meningioma patients were tested with a brief computerized 
neuropsychological test battery (i.e., CNS Vital Signs) that provides a rapid, efficient and cost-
effective screen for cognitive dysfunction (10). In this prospective follow-up study we examined 
the incidence and severity of cognitive dysfunction in meningioma patients before and 3 months 
after surgery, both at group level and individual patient level. We also evaluated possible changes 
in cognitive function after surgery. In addition, we examined status of cognitive functioning for 
different tumor locations and associations between tumor location and cognitive improvement 
over time, and evaluated anxiety and depression pre- and post-operatively.
PATIENTS AND METHODS
Patient population
The present study was part of a larger study in which neurosurgical patients, admitted for brain 
surgery at the Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands, are neuropsychologically 
assessed pre- and post-operatively. Cases eligible for the current analyses were patients diagnosed 
with a single meningioma who were treated with surgery between November 2010 and June 
2013. Most of these patients had a meningioma with a diameter > 3 cm, as we tend to adopt a 
wait-and-scan approach in patients with a smaller meningioma or treat them with Gamma Knife 
radiosurgery. Exclusion criteria were: age under 18, history of intracranial neurosurgery, history 
of psychiatric or neurological disorders, history of cranial radiotherapy, lack of basic proficiency 
in Dutch and total unfamiliarity with the use of computers. Patients who were unable to undergo 
the neuropsychological test battery due to severe cognitive problems were additionally excluded.
Procedure
The study was set up as a prospective follow-up design. One day before surgery, patients 
were hospitalized and tested. Post-operative assessment took place 3 months after surgery 
at neurosurgical follow-up. All patients were assessed with a standardized computerized 
neuropsychological test battery, CNS Vital Signs (CNS VS) (10). Test sessions were performed as 
part of the usual care in the Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands. Patients 
also filled out the Dutch translation of the Hospital Anxiety and Depression Scale (HADS) at both 
time-points (11). Results on the tests and questionnaires were evaluated in a multidisciplinary 
group (including a nurse, a neuropsychologist, and a rehabilitation physician) at 3 months after 
surgery. Socio-demographic information was collected by means of a checklist and interview. 
Clinical information was obtained from the electronic medical charts. 
The study was approved by the Medical Ethics Committee Brabant, The Netherlands (File  
number: NL41351.008.12).
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Instruments
Cognitive functioning was assessed by a computerized neuropsychological screening instrument, 
CNS VS, which consists of 7 tests (Table 1) (10). The pencil and paper versions of these tests are 
widely used by neuropsychologists. CNS VS has a normative database from 1,069 subjects ranging 
in age from 7 to 90, drawn from the American population. Testing results are presented in subject 
(raw) scores, age-matched standard scores, and percentile ranks. CNS VS standard scores have a 
mean of 100 and a standard deviation of 15; higher scores indicate better performance. The tests 
are assumed to be suitable for repeated testing because of the random presentation of stimuli, 
thereby minimizing practice effects. CNS VS has an official Dutch translation. The time needed to 
complete the battery is short, approximately 30–40 min (10).  
Depression and anxiety were assessed with a Dutch translation of the HADS (11). The HADS is a 
14-item self report screening scale which contains 7-item scales: 1 for anxiety and 1 for depression; 
both with a score range of 0–21. The HADS is considered to be unbiased by coexisting general 
medical conditions (12). The HADS has been validated in a Dutch sample (13). 
Table 1 CNS Vital Signs description of clinical domains and tests (10)
Domains Tests Description 
Memory Verbal memory test
Visual memory test
Learning a list of 15 words, with an immediate 
recognition, and after 6 more tests a delayed 
recognition trial
Learning a list of 15 geometric figures, with an 
immediate recognition, and after 5 more tests a 
delayed recognition trial
Processing speed Symbol digit coding Corresponding numbers and symbols
Executive functioning Shifting attention task Shifting from one instruction set to another 
quickly and accurately (matching geometric ob-
jects either by shape or by color)
Psychomotor speed Finger tapping
Symbol digit coding
Pressing the space bar with the right and left 
index finger as many times in 10 seconds
Above-mentioned
Reaction time Stroop test In the first part, pressing the space bar as soon 
as the words RED, YELLOW, BLUE, and GREEN 
appear
In the second part, pressing the space bar as 
soon as the color of the word matches what the 
word says
In the third part, pressing the space bar as soon 
as the word does not match what the word says
Complex attention Continuous performance test
Shifting attention task
Stroop test












Standard scores (i.e., scores normalized and corrected for age by CNS VS) were used in all analyses. 
We performed several one-tailed independent one-sample T-tests to explore whether meningioma 
patients differed from healthy controls (American normative database, M = 100, SD = 15 (10)) in 
cognitive functioning before and after surgery. To explore whether cognitive functions changed 
over time, two-tailed paired-samples T-tests were conducted. Effect sizes were calculated to 
determine the magnitude of the difference between patients and healthy controls and the change 
over time.
To gain insight in individual test performances, the number of patients scoring ‘low’ or ‘very 
low’ (i.e., 1.5 and 2 SD below average) was counted. These scores are indicated by CNS VS as 
‘moderate deficit and impairment possible or low’ and ‘deficit and impairment likely or very low’. 
The McNemar’s test of symmetry was used to compare the proportions of patients scoring low 
or very low before and after surgery. Cases of individual changes in severity (i.e., very low, low, 
low average, average, above average) of cognitive functioning from pre-test to post-test was 
calculated. 
To explore whether there was a difference in status of cognitive functioning for different tumor 
locations, two-tailed independent-samples T-tests were performed. Associations between tumor 
location and cognitive improvement over time were explored with Fisher’s exact tests.
Paired-samples T-tests were performed to explore whether there was a difference in anxiety 
and depression before and after surgery. A series of Pearson product-moment correlation 
coefficients was calculated to examine the strength of the relationship of anxiety and depression 
with cognitive performance.
Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) 
version 24.0. 
RESULTS
Demographic and clinical characteristics
Figure 1 shows the flow diagram for the study. Table 2 shows patients’ demographic and clinical 
characteristics. Mean age before surgery was 55 years and there was a female prominence (68%), 
which is similar to the normative database of CNS VS consisting of more women than men (ranging 
from 58 to 66%).
Test performance of meningioma patients at group level pre- and post-operatively
Meningioma patients showed significantly lower scores on all (7) cognitive domains both pre-
operatively and post-operatively, in comparison with the normative healthy American control 
group (p  < .05) (Table 3).
On the pre-operative assessment, medium effect sizes were found for psychomotor speed 
and reaction time. Medium (to large) effect sizes were found for memory, processing speed, and 
executive functioning. A medium to large effect was found for complex attention and cognitive 
flexibility. On the post-operative assessment, most of the effect sizes were small to medium, with 
the exception of psychomotor speed where a small effect size was found.
The two-tailed within-subjects analyses showed a significant change over time on 5 out of 
7 domains (p < .05) (Table 3). We observed significant improvements in the mean standardized 
domain scores on 5 out of 7 domains: memory, complex attention, cognitive flexibility, processing 
speed, and executive functioning. The effect sizes of change were small.
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Maximum tumor diameter (cm3; range) 4.38; 1.7 - 8 b
Epilepsy (N (%)) 16 (23.5)
Use of AEDs (N (%)) 14 (21.9) c
Radiotherapy within 3 months (N (%)) 1 (1.47)
Anxiety and depression (HADS)
  Anxiety pre-operatively mean (SD)
  Depression pre-operatively mean (SD)
  Anxiety post-operatively mean (SD)
  Depression post-operatively mean (SD)
6.73 ± 4.16 d
5.88 ± 4.22 d
5.08 ± 4.10 e
3.73 ± 3.12 e
a Education was classified according to the coding system of Verhage ranging from 1 (only primary school) 
to 7 (university) (14) 
b Data on volume of mass lesions was available in 67 of the 68 patients 
c Data on use of AEDs was available in 64 of the 68 patients due to missing reports  
d Data on pre-operative levels of anxiety and depression was available in 60 of the 68 patients 
e Data on post-operative levels of anxiety and depression was available in 52 of the 68 patients  




Figure 1 Flow of patients
Individual test performances of meningioma patients pre- and post-operatively
Individual patients that scored lower than 1.5 SD below average (‘low’ or ‘very low’ scores) were 
counted for each cognitive domain. Pre-operatively, 47 out of 68 patients (69%) scored low or 
very low in 1 or more cognitive domains. Thirteen out of 68 patients (19%) had deficits (low or 
very low scores) in more than 4 domains. In general, 43% of the patients (highest proportion) 
showed deficits on cognitive flexibility, followed by 41 and 37% of the patients with impairments 
on executive functioning and complex attention respectively.
Post-operatively, 27 out of 62 patients (44%) scored low or very low in 1 or more cognitive 
domains. Eight out of 62 patients (13%) had deficits on more than 4 domains. In general, the 
highest proportion of patients (26%) showed deficits on processing speed, followed by cognitive 
flexibility and reaction time (both 23%). According to the McNemar’s test of symmetry, there 
was a significant difference in the proportion of patients scoring low or very low on 1 or more 
domains pre- and post-operatively (p < .05). The test provides strong evidence of an improvement 
of cognitive functioning after surgery.
In addition, we determined the change in severity (i.e., very low, low, low average, average, 
above average) of cognitive functioning from pre-test to post-test (see Fig. 2). For all domains, 
most of the patients starting from the category ‘very low’ and ‘low’ made a positive change to 
categories of better cognitive performance after surgery. In particular, this positive change was 
most frequent for memory i.e., 21% of the patients improved 2 or more categories. For cognitive 
flexibility and executive functioning, 19 % of the patients improved 2 or more categories, followed 
by complex attention (18%), psychomotor speed (15%), reaction time (11%), and processing speed 
(10%). For all domains, the patients who scored ‘above average’ on the pre-test did not fall back to 
lower categories after surgery, with the exception of 1 patient who changed from ‘above average’ 
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to ‘very low’ on the domain reaction time. We could not find an explanation for this extreme 
decline in this patient.
Table 3 Comparison of means of the patient group at group level pre- and post-operatively
Variable Mean (SD) a Mean difference T-test       p            Effect size d b
Pre-operative assessment
Memory 86.63 (19.15) -13.37 -5.76 <.001*c .78
Psychomotor speed 90.31 (22.82) -9.69 -3.50 .001* .50
Reaction time 89.91 (19.28) -10.09 -4.32 <.001* .58
Complex attention 82.03 (27.86) -17.97 -5.32 <.001* .80
Cognitive flexibility 82.34 (27.26) -17.66 -5.34 <.001* .80
Processing speed 88.29 (17.85) -11.71 -5.41 <.001* .71
Executive functioning 84.40 (24.06) -15.60 -5.35 <.001* .78
Post-operative assessment
Memory 93.90 (17.64) -6.10 -2.72 .004*d .37
Psychomotor speed 95.34 (20.35) -4.66 -1.80 .038* .26
Reaction time 92.74 (21.20) -7.26 -2.70 .005* .40
Complex attention 90.77 (23.05) -9.23 -3.15 .002* .47
Cognitive flexibility 92.44 (22.60) -7.57 -2.64 .006* .39
Processing speed 93.55 (18.37) -6.45 -2.77 .004* .38
Executive functioning 93.94 (21.65) -6.07 -2.21 .016* .33
Pairs
1  - Memory 86.76 (19.07) 
93.90 (17.64)
-7.14 -3.221 .002* .39
2 - Psychomotor speed 90.61 (23.30)
95.34 (20.35)
-4.73 -1.757 .084 .22
3 - Reaction time 90.73 (19.14)
92.74 (21.20)
-2.01 -.768 .446 .10
4 - Complex attention 83.53 (28.28)
90.77 (23.05)
-7.24 -2.079 .042* .28
5 - Cognitive flexibility 84.24 (27.57)
92.44 (22.60)
-8.20 -2.518 .014* .33
6 - Processing speed 89.42 (17.88)
93.55 (18.37)
-4.13 -2.652 .010* .23
7 - Executive functioning 86.44 (23.95)
93.94 (21.65)
-7.50 -2.648 .010* .33
Note: N pretest = 68, N posttest = 62 
a CNS VS standard scores have a mean of 100 and a standard deviation of 15; higher scores indicate better 
performance 






Figure 2 Cognitive functioning from pre-test to post-test
The X-axis represents the patients scoring very low, low, low average, average, and above average on a domain 
pre-operatively (pre-op). The coloured blocks represent the number of patients post-operatively (post-op) in 
each category (i.e., different colours). For example for memory, pre-operatively 12 patients scored very low 
in the domain (total of all coloured blocks at very low), of whom post-operatively 2 patients kept a very low 
domain score, 2 had a low score, 4 improved to low average and 4 to an average domain score.
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Figure 2 Continued
The X-axis represents the patients scoring very low, low, low average, average, and above average on a domain 
pre-operatively (pre-op). The coloured blocks represent the number of patients post-operatively (post-op) in 
each category (i.e., different colours). For example for memory, pre-operatively 12 patients scored very low 
in the domain (total of all coloured blocks at very low), of whom post-operatively 2 patients kept a very low 





The X-axis represents the patients scoring very low, low, low average, average, and above average on a domain 
pre-operatively (pre-op). The coloured blocks represent the number of patients post-operatively (post-op) in 
each category (i.e., different colours). For example for memory, pre-operatively 12 patients scored very low 
in the domain (total of all coloured blocks at very low), of whom post-operatively 2 patients kept a very low 
domain score, 2 had a low score, 4 improved to low average and 4 to an average domain score.
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Figure 2 Continued
The X-axis represents the patients scoring very low, low, low average, average, and above average on a domain 
pre-operatively (pre-op). The coloured blocks represent the number of patients post-operatively (post-op) in 
each category (i.e., different colours). For example for memory, pre-operatively 12 patients scored very low 
in the domain (total of all coloured blocks at very low), of whom post-operatively 2 patients kept a very low 
domain score, 2 had a low score, 4 improved to low average and 4 to an average domain score.
Tumor location and pre-and post-operative cognitive functioning
With respect to cognitive functioning and tumor location, no significant differences in pre-
operative cognitive functioning were found between supratentorial and infratentorial tumors, 
between skull base and convexity tumors, and between skull base and convexity/falx tumors. 
Neither were there significant differences in pre-operative cognitive functioning between tumors 
located in the left or right hemisphere (all p’s > .05). In addition, no significant differences in post-
operative cognitive functioning were found between the tumor location groups, except for the 
domain of complex attention where a significant difference was found between supratentorial 
and infratentorial tumors, with better performance of the latter group (p < .05).
No significant associations were found between tumor location and cognitive improvement 
over time (p > .05). The proportion of patients who showed improvement in cognitive functioning 
following surgery was equal in patients with skull base tumors, convexity tumors and convexity/
falx tumors. No significant changes in cognitive functioning were found between left sided and 




Pre- and post-operative anxiety and depression
In general, on the pre-operative assessment 40 and 37% of the patients scored above the cut-off 
(≥ 8) for anxiety and depression, respectively. On the post-operative assessment, 33 and 10% of 
the patients scored above cut-off values on the anxiety and depression scales, respectively. On the 
pre-operative assessment, anxiety score was not significantly correlated with any of the cognitive 
domains (p > .05). Depression score significantly correlated negatively with psychomotor speed, 
reaction time, complex attention, cognitive flexibility, processing speed, and executive functioning 
(r ranging from -.29 to -.40). Following surgery there was a significant reduction in the levels of 
both anxiety and depression symptoms (p < .05). On the post-operative assessment, anxiety 
correlated negatively with complex attention (r = -.30). Depression was negatively correlated with 
memory and complex attention (r = -.28 and r = -.36).
DISCUSSION
This is the first prospective study that thoroughly investigated the incidence and severity of 
cognitive dysfunction of meningioma patients before and 3 months after surgery, and the change 
of cognitive dysfunction over time, both at group level and individual patient level.
Our findings indicate that the majority of meningioma patients already have mild to moderate 
cognitive deficits before surgery. They are faced with cognitive dysfunction in all cognitive domains 
tested: memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, 
processing speed, and executive functioning. Significant differences of medium to large effect 
size were found between our patients and the normative control group. Three months after 
surgery, test performance on 5 out of 7 domains (i.e., memory, complex attention, cognitive 
flexibility, processing speed, and executive functioning) improved significantly. For psychomotor 
speed and reaction time, no significant improvement was observed. In fact, psychomotor speed 
and reaction time were less impaired than other cognitive domains at baseline, which may have 
left less room for improvement. Although clear conclusions can be drawn about the existence of 
cognitive deficits in patients with meningioma, it must be noted that the observed deficits are of 
mild to moderate severity.
At the individual level, we found that pre-operatively, 47 out of 68 patients (69%) scored 
low or very low on 1 or more cognitive domains. Post-operatively, 27 out of 62 patients (44%) 
scored low or very low on 1 or more cognitive domains. Only a small proportion of the patients 
had cognitive deficits in more than 4 domains (i.e., 19% of the patients on the pre-operative 
assessment, and 13% of the patients on post-operative assessment). Most of the patients starting 
from the category ‘very low’ and ‘low’ made a positive change to categories of better cognitive 
performance after surgery. This positive change was most frequent for memory (21% of the 
patients changed ≥ 2 categories) and least frequent for processing speed (10% of the patients 
changed ≥ 2 categories). On average, surgery improves cognitive functioning, but still leaves a 
large proportion of meningioma patients with cognitive deficits 3 months after surgery. We are 
currently adding a 12-month follow-up to the design of our study to investigate possible further 
improvement over time and to identify the predictors of cognitive improvement in meningioma 
patients after surgery.
Our study demonstrates in addition that a brief computerized neuropsychological test 
battery is able to identify similar cognitive deficits as found in the study of Tucha et al. (3). Thus, 
a computerized test battery seems an adequate and time-efficient clinical instrument to detect 
cognitive impairments in meningioma patients.
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It may be suggested that low(er) pre-operative cognitive functioning on the day before surgery 
may be explained by high anxiety. However, there was no statistically significant correlation 
between pre-operative anxiety and pre-operative cognitive functioning, which makes this 
explanation unlikely. On the other hand, there was an association of pre-operative depression 
with cognitive function. Future research will help to better define the influence of preexisting 
depression with cognitive dysfunction after surgery. In general, on the pre-operative assessment 
most of the patients (60 and 63%) scored below the cut-off (≤ 8) for anxiety and depression 
respectively. On the post-operative assessment, there was a significant reduction of both anxiety 
and depression symptoms (i.e., 77 and 90% of the patients scored below the cut-off for anxiety 
and depression respectively).
A Dutch control group was not available. We compared the standard scores of the patients 
on 7 cognitive domains with the normative healthy American control group from CNS VS. In an 
earlier study we found that the performance on CNS VS tests of the Dutch control group of healthy 
participants was comparable to the American control group (14). Therefore, we consider it unlikely 
that the interpretations of the results of our Dutch meningioma group are flawed by comparison 
with an American control group.
CNS VS as an instrument has a few shortcomings. CNS VS is assumed to be suitable for 
repeated testing because of the random presentation of stimuli (10). Despite the chance that a 
patient exactly gets the same stimuli twice is negligible, there still could be a learning effect of 
the battery in general: the patient knows what to expect the second time. This phenomenon is 
also known as test-wiseness, which means that a test-taking strategy can be taught by instruction 
and that the knowledge gained will enable a test-wise examinee to obtain a higher score than 
an equally knowledgeable examinee who lacks test sophistication (14). However, we included a 
Dutch control group (N = 20) in addition to the American control group in our study on cognitive 
deficits in patients with trigeminal neuralgia with the aid of CNS VS (14) and found no effects of 
repeated testing.
We are aware that for some patients computerized testing is more stressful than for others, 
for example for older patients who are not familiar with computers (18). Iverson and colleagues 
(19) found that people with ‘frequent’ computer use performed better than people with ‘some’ 
computer use on tests requiring rapid visual scanning and keyboard work. In our study, we have 
noticed that when patients are too slow, they cannot follow the test correctly and have lower 
scores in all cognitive domains (memory, executive functioning etc.). We excluded patients 
with total unfamiliarity with computers. Neuropsychological technicians of computerized 
neuropsychological tasks should therefore be aware of the difference that may exist between 
patients with low versus high frequent computer familiarity.
In this study most of the patients had a meningioma with a diameter > 3 cm. All patients were 
selected for surgical treatment. With regard to smaller meningiomas we tend to adopt a wait-
and-scan approach or treat them with Gamma Knife radiosurgery. Performance in our group of 
surgically treated patients may be slightly worse than performance in the whole population of 
meningioma patients probably due to symptomatic mass effect. Therefore, it is difficult to compare 
and generalize the results of this study to patients with smaller meningiomas.
Five patients were excluded due to severe cognitive problems because they were not capable 
of undergoing assessment with CNS VS. As a result, the incidence and severity rates of cognitive 
dysfunction may be an underestimation in this patient group.
We did not find significant differences in pre-operative and post-operative cognitive 




operative performance was better for patients with infratentorial tumors. In line with Tucha and 
colleagues, we did not find significant differences between left sided and right sided tumors in 
either the pre- or post-operative assessment (3). On the other hand, Dijkstra and colleagues 
found that left sided as opposed to right sided tumors were more related to verbal deficits after 
treatment (4). The lack of effect of laterality in cognitive results between left sided and right 
sided hemisphere meningioma tumors could be explained by the fact that CNS VS has a smaller 
verbal emphasis than other neuropsychological batteries often have. No significant associations 
were found between tumor location and cognitive improvement over time. In a follow-up study 
we will investigate predictors of cognitive functioning in a larger group of meningioma patients.
We did not investigate other variables that are associated with neuropsychological functioning 
in meningioma patients. For example, epilepsy, anti-epileptic drugs, and other psychological factors 
may negatively affect neurocognitive functioning in meningioma patients (4, 5). Specification of 
predictors on cognitive functioning was beyond the scope of this study that merely aimed to 
report on incidence and severity.
CONCLUSION
We conclude that meningioma patients are faced with cognitive dysfunction in several cognitive 
domains both pre- and 3 months post-operatively. After surgery, cognitive functioning improved 
in a large proportion of patients, although most cognitive deficits are of mild to moderate 
severity. Our study also demonstrates that a rapid, efficient and cost-effective computerized 
neuropsychological test battery is a good alternative for conventional, time-consuming 
neuropsychological testing.
Based on the results of this study, clinicians and patients can be better informed about 
cognitive dysfunction in meningioma patients. We expect that diagnosis and treatment of these 
cognitive deficits will improve outcomes and quality of life in meningioma patients by providing 
appropriate care (for example cognitive rehabilitation (20)), adjusted to the cognitive profile of 
the individual patient.
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Computerized neuropsychological test (CNT) batteries have become increasingly popular in 
clinical and research settings over the past years. A major advantage of CNT’s is the potential of 
having computers perform labor-intensive test administration, and accurate as well as less time 
consuming scoring procedures. The Central Nervous System Vital Signs (CNS VS; (1)) is a battery 
composed of CNTs that are mostly based on well-established conventional paper-and-pencil tests. 
CNS VS has been shown to be well suited for use as a brief clinical screening tool for cognitive 
dysfunction in different patient groups (1-3). 
However, in spite of their widespread use and clinical utility, many CNT’s, including CNS VS, 
are limited in terms of their psychometric development, and stratified norms are often lacking 
(4, 5). Most of the normative data have been collected and described by Gualtieri and Johnson (1) 
more than a decade ago based on a sample of 1,069 volunteering American participants ranging 
in age from 7 to 90 years. Since 2006, the normative database has been expanded to over 1,900 
participants (http://www.cnsvs.com), but unfortunately no information on the updated CNS 
VS normative database has been reported to date. As a result, there is no publically available 
description of the composition of the American sample regarding background characteristics, 
nor the basis on which participants were classified as “normal,” except that they had “no past or 
present neurological or psychiatric disorder, head injury, and learning disabilities” (1). Hence, the 
representativeness of the norms for the American population cannot be evaluated and is uncertain. 
Moreover, although the CNS VS has been translated into over 50 languages, only normative data 
for the American version has been published. However, the performance on translated versions of 
the CNS VS could be affected by cultural influences rendering the norms for the American sample 
inapplicable to individuals in other countries. To the best of our knowledge, the applicability of the 
original norms to non-American samples has never been studied. In addition, the original CNS VS 
norms may be outdated, since norms were based on data that were collected over a decade ago. 
Ageing of norms is an important treat to the usefulness of normative data (e.g., (6)).
Another limitation of the original CNS VS’ normative data concerns the absence of 
adjustments for effects of education and sex, as normalized scores are solely age-corrected. All 
3 sociodemographic variables (i.e., age, education, and to a lesser extent sex) have extensively 
been found to correlate with performance on various neuropsychological tests (7, 8), including 
performance on computerized tests (9-11). The absence of corrections for these variables 
when interpreting performance on neuropsychological tests hinders proper interpretation and 
comparison in terms of cognitive functioning.
In the current study, we evaluated the performance of a sample of healthy Dutch participants 
on the CNS VS against the original American normative data. In addition, we evaluated the impact 
of the sociodemographic variables age, education, and sex on performance using a regression-
based procedure. By using this approach, individual normed scores can be derived. Formulae for 
obtaining sociodemographically adjusted normed scores based on normative data from the Dutch 
population are presented as well.
METHOD
Participants and Procedure
A total of 158 Dutch participants, recruited by convenience sampling from the broad network 
of the research group, volunteered to participate in the study. Participants were considered 
healthy if (a) there was no past or present psychiatric or neurologic disorder; (b) they had no 
other major medical illnesses in the past year prior to participation (e.g., cancer, myocard infarct); 
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(c) they were free of use of any centrally acting psychotropic medication; and (d) did not have 
a history of or current alcohol or drug abuse. The computerized neuropsychological tests were, 
depending on participants’ preference, administered individually at Tilburg University (Tilburg, The 
Netherlands), Elisabeth-TweeSteden Hospital (Tilburg, The Netherlands), or at participants’ homes. 
Well-trained test technicians ensured appropriate conditions and remained present during the 
entire assessment. Participants provided written informed consent and filled out a questionnaire 
on health status.
The study was approved by the Medical Ethics Committee Brabant, The Netherlands (File  
number: NL41351.008.12).
Table 1 Description of educational levels
Level Verhage categories a
Low 1. Less than 6 years of primary education
2. Finished primary education
3. Primary education and less than 2 years of low-level secondary education
4. Finished low-level secondary education
Middle 5. Finished average-level secondary education
High 6. Finished high level secondary education
7. University degree
a Adapted from Verhage (12)
Measures and Normative Data
Sociodemographic Characteristics. Number of years and completed level of education were 
self-reported by participants. Grade retention did not count as an extra year, neither did 
supplementary vocational courses that were attended after graduation. Actual number of years 
of education was verified (i.e., recalculated by the test technician together with the participant) 
during the assessment. To classify the level of education, the Dutch Verhage scale was used (12). 
Its 7 categories were merged into 3 ordinal categories: low educational level (Verhage 1 until 
4), middle educational level (Verhage 5), and high educational level (Verhage 6 and 7; Table 1). 
Participants also rated their frequency of computer use on a 3-point scale with categories never, 
some, or frequent.
Central Nervous System Vital Signs. Cognitive functioning was assessed using the Dutch translation 
of the CNT battery CNS VS. It comprises 7 neuropsychological tests, yielding measures of 
performance in 11 cognitive domains. Since some domains scores generated by CNS VS are very 
similar (i.e., mainly calculated based on components of the same tests), we chose to consider only 
7 cognitive domains (Table 2). Time needed to complete the total battery is approximately 30 to 
40 minutes. Scoring is automated and scores are presented in raw and normed scores, as well as 
percentile ranks, generating a summary report for clinical interpretation or statistical analysis. 
Raw scores include the number of correct or incorrect responses, reflecting accuracy, and mean 
reaction times (in milliseconds) on individual tests and domains, reflecting speed. Normed scores 
are automatically generated by the CNS VS and represent the performance of an individual relative 
to the American normative sample controlled for age. In the population, CNS VS normed scores 
are assumed to have a mean of 100 and a standard deviation of 15; higher scores always indicate 




normative sample that are equal to or lower than the score at hand. All testing was done using CNS 
VSX’ local software app, on the same type of laptop computers running Windows 7 Professional 
on 64-bit operating systems. Background programs were shut down at time of all assessments 
and laptops were disconnected from (wireless) internet resources.
There is not a large body of literature regarding the reliability and validity of CNS VS. In the 
original reliability and validity paper, Gualtieri and Johnson (1) describe CNS VS’ psychometric 
characteristics to be very similar to the characteristics of the conventional neuropsychological 
tests on which the battery is based. However, correlational studies suggest at best moderate 
correlations between CNS VS and traditional neuropsychological tests, and in addition, no 
consistent clear patterns of convergent or discriminant validity have been determined (1, 9, 13-
15). As no 2 presentations of CNS VS are similar due to the random presentation of stimuli, the 
battery is assumed to be suitable for serial administration without inducing practice effects. 
Table 2 Supplementary material on central nervous system Vital Signs (CNS VS)
Cognitive domain CNS VS test
Domain score calculations 
(“Formulas for Calculating 
Domain Scores,” n.d.) (16) Description
Verbal memory Verbal 
memory test 
(VBM)
VBM direct correct hits + 
VBM direct correct passes + 
VBM delayed correct hits + 
VBM delayed correct passes
Learning a list of 15 words, with 
a direct recognition, and after six 
more tests a delayed recognition 
trial
Visual memory Visual 
memory test 
(VIM)
VIM direct correct hits + 
VIM direct correct passes + 
VIM delayed correct hits + 
VIM delayed correct passes
Learning a list of 15 geometric 
figures, with a direct recognition, 
and after six more tests a delayed 
recognition trial




Number 1 to 9 correspond to dif-
ferent symbols. As many correct 
numbers as possible have to be 
filled out underneath the present-
ed symbols in 90 seconds
Psychomotor speed Finger-tapping 
test (FTT); SDC
FTT taps right hand + FTT 
taps left hand + SDC correct 
responses
Pressing the space bar with the 
index finger as many times in 10 
seconds, above mentioned
Reaction time Stroop test 
(ST)
(ST Part II reaction time on 
correct responses + ST Part 
III reaction time on correct 
responses)/2
In Part I, pressing the space bar as 
soon as the word RED, YELLOW, 
BLUE, and GREEN appear—In Part 
II, pressing the space bar as the 
color of the word matches what 
the word says—In Part III, pressing 
the space bar as the color of the 
word does not match what the 
word says






Stroop commission errors + 
SAT errors + CPT commis-
sion errors + CPT omission 
errors
Responding to a target stimu-
lus “B” but no any other letter. 
Shifting from one instruction to 
another quickly and accurately 
(matching geometric objects 
either by shape or color); Above 
mentioned
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Statistical Analysis
Mean Domain and Test Performance. To explore whether mean CNS VS performance of the Dutch 
participants differed from the mean performance of the normative American sample, a series 
of two-tailed one-sample Z-tests was performed (M = 100, SD = 15). CNS VS presents up to 10 
different mean raw scores (i.e., for each of the 10 different age-groups of CNS VS’ normative 
sample) for each domain and test. Since adopting the same subgroups in the Dutch sample 
would dramatically decrease the sample size for these analyses, the automatically generated 
age corrected normed scores were used in all comparisons between the American and Dutch 
samples. In this way, we also account for effects of age in both groups. Effect sizes (ES) for potential 
differences between the American and the Dutch samples were calculated and expressed as 
Cohen’s d using pooled variance. ES between ≤ .20 and .49 were defined as small, between .50 
and .79 as medium, and ≥ .80 represented large effects (17). 
Multiple Regression Analyses. To explore the effects of sociodemographic factors on CNS VS 
performance, a series of multiple linear regression analyses was conducted using raw CNS VS 
domain scores as the outcome variables and a predetermined list of sociodemographic predictors. 
Age (in years), education (dummy coded; middle education as reference category), and sex (coded 
as 0 = men, 1 = women) were predictor variables which were entered as a single block (“enter” 
method). Assumptions were evaluated as follows: independence of observations was evaluated 
by Durbin–Watson tests (18), and linearity and homoscedasticity were examined using scatter 
plots of residuals. Potential multicollinearity between predictors was examined by inspecting 
Pearson’s correlation coefficients. By computing Cook’s distances, univariate influential cases 
were identified (19). Normality of residuals was investigated by visual inspection of histograms. 
Alpha was set at .02 in order to prevent the problem of inflated Type I errors related to multiple 
comparisons. All statistical analyses were performed with SPSS 22.0.
Normative Regression Formulae. The results of the regression models which regresses performance 
on age, sex, and educational level also provide the formulae for computing sociodemographically 
adjusted norms. Clinicians and researchers can use these formulae in future administrations of 
CNS VS to obtain normed scores for individuals on each cognitive domain, based on their age, 
educational level, and sex. In particular, all predictors were included in the normative formulae 
irrespective of the significance of the effect, as follows:
Yp domain = α + b1Age + b2Dlow education + b2Dhigh education + b3Sex
In this formula, Yp domain is the predicted raw domain score, α is the intercept, and b1 trough 
b3 are the regression coefficients. Notice that educational level is a categorical variable with 3 
categories and therefore modeled by means of 2 dummy variables, 1 for low education and 1 for 
high education (i.e., middle education as reference category). Sex is also a dummy variable, with 
men as the reference category (i.e., for men: sex = 0 and for women: sex = 1). Application of these 




Box 1 Application of sociodemographically adjusted normative formulae and a real-life example
1.  Complement the formula: Yp domaina = α + b1 age + 
b2 low education + b2 high education + b3 sex, with the assessed 
individual’s age, education, and sex: this will result 
in a predicted raw score (Yp) for each cognitive 
domain.
Consider a 68-year-old male patient who completed 
a high educational level, and obtained a raw score of 
27 on processing speed. His predicted raw score for 
processing speed is  Yp processing speed = 77.38 + (−0.52 * 
age) + (−3.16 * educationlow + 3.98 * educationhigh + 2.42 
* sexwoman), with age = 68, educationlow = 0, educationhigh 
= 1, sexwoman = 0, resulting in Yp processing speed = 46.
2.  Subtract the predicted raw score from the 
individual’s obtained (Yo) raw score, now a 
difference score is generated: Yo − Yp.
The predicted raw score = 46, subtracted from the 
obtained raw score (27) results in a difference score 
of −19.
3.  The individual’s Z-score is computed as 
follows: Z-score = Yo − Yp/SDresidual, where SDresidual 
is the SD of the sample’s residual, reflecting the 
accuracy of predictions made by the regression 
line.
Dividing the difference score by the SDresidual of 
processing speed = 8.88 (see Table 6), results in Z = 
−19/8.88 = −2.14.
4.  The Z-score can be interpreted via a 
Z distribution. As higher raw scores on reaction 
time and complex attention indicate worse 
performance, Z-scores for these domains have 
to be multiplied by −1 to facilitate consistent 
interpretation of z over all cognitive domains (i.e., 
positive Z-scores indicate a higher obtained raw 
score relative to others of similar age, education, 
and sex, and vice versa for negative Z-scores).
With a Z-score of −2.14, performance on processing 
speed is more than 2 SD lower than expected given 
the patients’ age, education, and sex, which indicates 
(serious) impairment. The obtained raw score of this 
patient is represented by a CNS VS (age corrected) 
normed score of 78 (labeled by CNS VS as “below 
the expected level”), corresponding to a Z-score of: 
78−100/15 = −1.47 (as compared to −2.14).
Note. CNS VS=Central Nervous System Vital Signs
aAge in years, sex: 0=man, 1=woman; education: low (educationlow=1, educationhigh=0), middle (educationlow=0, 
educationhigh=0), and high (educationlow=0, educationhigh=1) 
RESULTS
Sociodemographic Characteristics
Table 3 shows participants’ sociodemographic characteristics. Mean age was 45.9 (SD = 14.4) 
years, ranging from 20.0 to 80.0. There was a female predominance (57%) in the Dutch sample, 
which appears comparable to the American normative database of CNS VS. The participants 
completed 16.9 years of education on average. Almost all participants (97%) indicated to use the 
computer frequently. Men and women did not differ in terms of mean age, t(156) = 0.48, p= .162, 
and educational level, χ2(2) = 1.20, p = .550, neither did men and women differ in frequency of 
computer use, χ2(2) = 1.42, p= .491. Likewise, no significant differences between groups based on 
the 3 educational levels were found concerning age, F(2, 155) = 1.04, p = .355, and frequency of 
computer use, χ2(4) = 8.79, p= .067.
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Table 3 Sociodemographic characteristics of the Dutch sample (N = 158) and the American sample (N = 1,069)
Dutch sample American sample a



































a Characteristics of the American sample were not presented for the sample as a whole (see Gualtieri and 
Johnson (1) for demographic characteristics across different age groups)
Mean Domain and Test Performance
Table 4 shows mean differences for the Dutch sample as compared with the American-based 
normed scores (M = 100, SD = 15). Significant mean differences were found for the domains of 
processing speed (mean difference = 4.52, SD = 14.48; z = 3.77, p < .001), psychomotor speed 
(mean difference = 7.17, SD = 12.87; z = 5.97, p <. 001), and cognitive flexibility (mean difference 
= 2.91, SD = 12.94; z = 2.39, p= .017), where the Dutch sample demonstrated higher scores than 
the American normative sample. ES were small (Cohen’s d respectively .19 and .30 for cognitive 
flexibility and processing speed), except for psychomotor speed with a difference of near-medium 
size (Cohen’s d = .49).
At the level of normed individual test scores (e.g., representing reaction time, number of 
correct answers), the Dutch sample demonstrated significantly higher scores on 5 out of 17 
measures compared with the American normative sample (see Table 4). The number of correct 
rejections in the delayed recognition visual memory task was significantly higher in the Dutch 
sample, and Dutch participants performed significantly more taps on the Finger Tapping Test with 
both the right and the left hand. In addition, the numbers of correct responses on the Symbol 
Digit Coding task and Shifting Attention Task were higher in the Dutch compared with the original 
American normative group. A near-medium sized difference was found for the right hand Finger 




Table 4 Mean CNS VS normed scores of Dutch participants (N = 158) compared with the American normative 







Verbal memory 98.66 (14.99) −1.34 −1.11 .268 −.09
Visual memory 101.81 (12.98) 1.81 1.50 .133 .12
Processing speed 104.52 (14.48) 4.52 3.77 <.001* .30
Psychomotor speed 107.17 (12.87) 7.17 5.97 <.001* .49
Reaction time 101.41 (11.13) 1.41 1.17 .242 .09
Complex attention 101.88 (11.66) 1.88 1.54 .124 .13
Cognitive flexibility 102.91 (12.94) 2.91 2.39 .017* .19
Test
Verbal memory test
Direct recognition correct hits 99.01 (14.66) −0.99 −0.79 .425 −.07
Direct recognition correct rejections 100.94 (12.58) 0.94 0.76 .447 .06
Delayed recognition correct hits 98.16 (14.86) −1.84 −1.48 .138 .12
Delayed recognition correct rejections 98.98 (14.07) −1.02 −0.89 .370 .08
Visual memory test
Direct recognition correct hits 99.50 (13.97) −0.50 −0.40 .685 .03
Direct recognition correct rejections 102.53 (13.35) 2.53 2.05 .040 .17
Delayed recognition correct hits 98.46 (12.06) −1.54 −1.25 .211 −.10
Delayed recognition correct rejections 103.86 (11.43) 3.86 3.13 .002* .26
Finger-tapping test
Number of taps right 106.79 (12.66) 6.79 5.52 <.001* .46
Number of taps left 104.81 (12.99) 4.81 3.92 <.001* .33
Symbol digit coding test
Number correct 105.37 (14.27) 5.37 4.39 <.001* .36
Stroop test
Reaction time Part I 101.11 (10.01) 1.11 0.91 .364 .08
Reaction time Part II 100.48 (12.78) 0.48 0.39 .698 .03
Reaction time Part III 102.34 (10.48) 2.34 1.90 .057 .16
Shifting attention test
Number correct 102.97 (14.16) 2.97 2.42 .016* .20
Reaction time 100.51 (15.13) 0.51 0.42 .678 .03
Continuous performance test
Number correct 101.67 (9.48) 1.67 1.37 .172 .12
Note. CNS VS = Central Nervous System Vital Signs 
a CNS VS normed scores based on the American normative sample have a mean of 100 and a standard 
deviation of 15; higher scores indicate better performance; positive mean difference indicates better per-
formance for the Dutch sample and vice versa 
b Cohen’s d effect sizes: ≤.20 to .49, small; .50 to .79, medium; ≥.80, large (17)
*p < .02
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Multiple Regression Analyses
None of the assumptions regarding the regression analyses were violated. There was independence 
of residuals, with Durbin–Watson statistics ranging from 1.72 to 2.22. Scatter plots demonstrated 
linear relationships between the dependent and independent variables, and homoscedasticity. No 
problems with collinearity were identified, with correlations r between −.01 and .38. No influential 
cases were identified (all Cook’s distances >1), and histograms demonstrated normally distributed 
standardized residuals for each cognitive domain.
Table 5 shows the results of the regression analyses. Overall, significant effects of age were 
found on performance in 4 out of 7 raw cognitive domains scores (i.e., for processing speed, 
psychomotor speed, reaction time, and cognitive flexibility). Higher age was consistently 
associated with lower scores. Educational level was significantly associated with performance 
on 3 out of 7 domains: participants with a high educational level (i.e., compared with a middle 
and low educational level) obtained higher scores on visual memory, processing speed, and 
cognitive flexibility. Sex was found to be significantly associated with performance on the verbal 
memory domain, in favor of women, and the psychomotor speed domain, in favor of men. The 
proportions of explained variances (R2) by age, education, and sex ranged from 7.2% (for the verbal 
memory domain) up to 46.2% (for the processing speed domain). Hierarchical regression analyses 
demonstrated significantly more explained variance for a model including both age and education, 
compared with a model with solely age, in 4 out of 7 cognitive domains. In 2 out of 7 domains 
adding the factor sex on top of age and education resulted in significantly more variance explained. 
Adding education or sex (in addition to age) to the regression model significantly increased the 
explained variance for the cognitive domains, except for the reaction time domain, where only 
age contributes significantly (data not shown). 5
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Table 5 Multiple regression based on the Dutch sample (N = 158): association of age, education, and sex with 
raw cognitive domain scores of CNS VS
Cognitive 










Age −0.03 0.03 −0.08 0.03 .320
Educationlow −0.21 1.21 −2.61 2.18 .861
Educationhigh 1.49 0.79 −0.07 3.05 .062




Age −0.06 0.02 −0.10 −0.01 .021
Educationlow −0.92 1.12 −3.13 1.29 .415
Educationhigh 1.79 0.73 0.35 3.22 .015*




Age −0.52 0.05 −0.62 −0.42 <.001*
Educationlow −3.16 2.41 −7.91 1.60 .191
Educationhigh 3.98 1.56 0.92 7.06 .011*




Age −0.87 0.09 −1.05 −0.68 <.001*
Educationlow 0.22 4.5 −8.65 9.09 .960
Educationhigh 5.56 2.91 −0.18 11.31 .058




Age 1.65 0.39 0.88 2.42 <.001*
Educationlow −11.43 19.09 −49.17 26.30 .550
Educationhigh −20.51 12.11 −44.43 3.42 .092




Age 0.03 0.02 −0.02 0.08 .189
Educationlow 2.60 1.17 0.29 4.90 .027
Educationhigh −1.30 0.73 −2.75 0.14 .076




Age −0.28 0.06 −0.40 −0.17 <.001*
Educationlow −6.16 2.82 −11.76 −0.57 .031
Educationhigh 5.05 1.81 1.48 8.62 .006*
Sexwoman −1.63 1.69 −4.98 1.72 .337
Table 5: note. CNS VS=Central Nervous System Vital Signs; df=degrees of freedom; SE Β=standard error Β; 
95% CI Β=95% confidence interval Β. Coding of predictors: age in years; low level of education: eductionlow= 1, 
educationhigh= 0; middle level of education: educationlow=0, educationhigh=0; high level of education: 
educationlow=0, educationhigh=1; sex: man=0, woman=1
a Higher scores indicate lower performance
* p < .02
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Normative Regression Formulae
Table 6 shows the regression formulae that can be used to calculate normed predicted scores 
(i.e., corrected for effects of age, education, and sex) on cognitive domains of CNS VS for the 
Dutch population. An example of the application of the sociodemographically adjusted normative 
formulae is shown in Box 1.
Table 6 Regression formulae based on the Dutch sample (N = 158).
Cognitive 
domain Regression equation a SDresidual
Verbal 
memory
50.93 + (−0.03 * age) + (−0.21 * educationlow + 1.49 * educationhigh) + (1.77 * sexwoman) 4.47
Visual 
memory
47.33 + (−0.06 * age) + (−0.92 * educationlow + 1.79 * educationhigh) + (0.83 * sexwoman) 4.12
Processing 
speed
77.38 + (−0.52 * age) + (−3.16 * educationlow + 3.98 * educationhigh) + (2.42 * sexwoman) 8.88
Psychomo-
tor speed
219.00 + (−0.87 * age) + (0.22 * educationlow + 5.56 * educationhigh) + (−7.44 * sexwoman) 16.58
Reaction 
timeb
590.03 + (1.65 * age) + (−11.43 * educationlow + −20.51 * educationhigh) + (−20.71 * sexwoman) * −1 69.03
Complex 
attentionb
5.07 + (0.03 * age) + (2.60 * educationlow + −1.30 * educationhigh) + (0.65 * sexwoman) * −1 4.13
Cognitive 
flexibility
58.51 + (−0.28 * age) + (−6.16 * educationlow + 5.05 * educationhigh) + (−1.63 * sexwoman) 10.21
Note. Age in years, sex: 0 = man and 1 = woman; education: low (educationlow = 1, educationhigh = 0), middle 
(educationhigh = 0, educationlow = 0), and high (educationlow = 0, educationhigh = 1). SDresidual = standard devia-
tion of the sample’s residual. p < .02 in bold
a Yp domain = – + b1Age + b2Dlow education + b2Dhigh education + b3Sex. 
b Higher scores indicate lower performance
DISCUSSION
We examined the performance of a group of healthy Dutch participants who underwent 
neuropsychological examination with the computerized neuropsychological battery CNS VS. The 
purpose of this study was threefold: (a) to examine the applicability of the American CNS VS 
norms for the Dutch population; (b) to examine the effects of age, education, and sex on CNS VS 
performance of the Dutch sample; and (c) to provide sociodemographically adjusted normative 
formulae for the Dutch population.
At the level of individual CNS VS tests, scores in the Dutch sample were significantly higher 
on 5 out of 17 measures. Consequently, differences in mean performance for 3 out of 7 cognitive 
domains were found between the Dutch sample and the American normative sample; in the 2 
domains covering different types of speed, namely processing and psychomotor speed, and in 
cognitive flexibility.
It should be noted that computer skills - including keyboard work and on - screen visual 
scanning - have improved tremendously over the past decade, which may result in improvements 
in overall performance on computerized neuropsychological speed tests. Indeed, an earlier study 
on computer familiarity and CNS VS performance demonstrated significantly better (i.e., faster) 
performance in people who are very familiar with computers, opposed to people who reported 




of computers nowadays, our sample comprised too few participants with only some or none 
computer familiarity to look into these effects. The beneficial effects of computer familiarity may 
(partly) explain the differences between the American 2006 group and the Dutch 2016 group.
In addition, a possible Flynn effect should be considered given the headspring of the normative 
data presented by CNS VS. The Flynn effect refers to a substantial rise of the population’s 
performance on tests of intelligence in developed countries, typically about 3 to 5 points (i.e., on 
a IQ scale with a mean of 100 and standard deviation of 15 points) per decade. Explanations for 
the Flynn effect include genetic, environmental, methodological, and measurement factors (21, 
22). It has been found that the impact of the Flynn effect extends beyond the measurement of 
IQ and has, for example, been demonstrated on measures of memory (23, 24), processing speed, 
and cognitive flexibility (25), with gains comparable to the size of the Flynn effect on measures 
of IQ. The scale of normed scores of CNS VS tests and domains is similar to that of IQ points, and 
the original normative data presented by Gualtieri and Johnson (1) have been established over 
a decade ago. Therefore, mean normed cognitive domain scores can be expected to be about 
3 to 5 points higher in the current 2015/2016 sample than the original normative data—which 
corresponds to the increased scores found in the present study.
Since the total variance explained by the sociodemographic variables added up to almost 50% 
in the present study (i.e., in particular for the processing speed and psychomotor speed domain), 
the influence of age, sex, and education should be taken into consideration when interpreting 
performance on the CNS VS. CNS VS incorporated corrections for age in their normative evaluation, 
but did not correct for effects of education and sex. Consistent with the literature, higher age was 
associated with lower performance (26). Educational level was found to be positively associated 
with performance on visual memory, processing speed, and cognitive flexibility. Highly educated 
participants are likely to be somewhat overrepresented in our Dutch sample relative to the general 
Dutch population (CBS Statistics Netherlands, http://statline.cbs.nl/ Statweb/). Although the higher 
performance of the sample might also be explained by this factor, we have no information on 
education in the original American normative sample, as these data are not disclosed by the 
authors. We may assume that this sample also included a relatively high proportion of highly 
educated participants, as these are typically (more) interested in study participation (27). As would 
be expected, sex did not play a large role, except for the verbal memory domain favoring women, 
and the psychomotor speed domain favoring men. These findings are consistent with literature 
on sex differences in performance on other (computerized) tests (10, 28, 29), and reported by 
Gualtieri (30) who examined sex differences in a subset of participants who completed the CNS 
VS battery during its standardization study.
Based on the collected data, we established regression-based normative formulae to adjust 
for the effect of sociodemographic variables on CNS VS performance. In future evaluations of 
performance in our (Dutch) patient studies, these normative data will replace the American norms.
Some critical remarks are in order with respect to the current study. Presented results are 
based on performance in Dutch healthy participants recruited on availability (i.e., convenience 
sampling). A disadvantage of this method includes the risk that the sample might not represent 
the Dutch population as a whole. As stated above, a relatively small number of low-educated 
participants (i.e., 12% compared with approximately 35% in the general Dutch population (CBS 
Statistics Netherlands, http://statline.cbs.nl/ Statweb/) was included in the present study. The 
regression-based method requires smaller samples since continuous covariates do not have to 
be categorized (e.g., stratifying the sample into groups of different age, sex, and educational 
levels). Instead, it makes optimum use of the entire sample to estimate the normative statistics 
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and the regression model (31, 32). However, one should always be careful when using these 
data for interpreting individual test performance of people who are in the extreme ends of age, 
or education (very low levels, or by contrast, very high levels of education). In addition, data 
were collected using a Dutch translation of the CNS VS battery. Since the equivalence with the 
English version of the test has never been confirmed, we cannot rule out that differences in 
difficulty due to translation of instructions and items also have a share in the observed differences 
(33). Although our results may not be generalizable to other countries or to populations who 
speak other languages, they demonstrate that CNS VS users from other populations than the 
American should use and interpret the original norms with caution. Moreover, we recommend 
on considering adjusting for sociodemographic factors when interpreting CNS VS performance 
in American populations.
Also, changes in technology (i.e., computer hardware/ software) since the collection of the 
initial American norms may have affected important parameters including timing accuracy. 
Although technical aspects and settings of the devices used in the present study were the 
same for all assessments, no information is available concerning devices that were used when 
collecting the American normative data. Differences therein might explain a small portion of the 
group differences in our study, but this is unlikely considering the generally rather small timing 
inaccuracies and the significant differences that we demonstrated for cognitive domains (34, 
35). Yet, although the timing precision of CNS VS on different test systems should be explored 
in more detail, CNS VS provides explicit recommendations concerning system requirements for 
installation, and states that their applications are designed to be working equally well over types 
of devices and types of applications (‘CNS Vital Signs Optimal Use Installation Guide’, http://www.
cnsvs.com). However, evidence of this statement is not available.
Future studies should consider the psychometric robustness of CNS VS across cultures and 
(other) non-American languages. Furthermore, various clinical and research settings require 
repeated neuropsychological assessment, for example, for the evaluation of effects of intervention 
on cognitive functioning. This emphasizes the need for inspection of CNS VS regarding repeated 
assessment, addressing practice effects (i.e., improvements in performance due to familiarity with 
the test, its items, and test procedures opposed to true cognitive improvement). Currently, we are 
performing follow-up assessments in the same Dutch sample with the aim of establishing change 
indices correcting for potential practice effects and measurement errors to determine “true” (i.e., 
reliable) clinically meaningful cognitive change when administering CNS VS repeatedly over time.
The present study examined the applicability of the original American normative data of CNS 
VS to a non-American population: our results call the usefulness of the 2006 norms of the CNS VS in 
other populations than the American into question. Furthermore, we identified effects of education 
and sex, in addition to known effects of age, on CNS VS performance. These findings highlight the 
need for more up-to-date population-based norms for CNS VS performance. Sociodemographic 
factors should be considered when interpreting performance on this measure, for example, by 




A SPSS syntax for converting raw cognitive domain scores into z 
scores is available by contacting the authors.
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The vast majority of patients with intracranial meningioma can be cured by surgery (1). However, 
meningioma patients suffer from deficits in several cognitive domains already before surgery (2). 
Surgical resection of the meningioma has been found to improve cognitive performance of patients, 
but post-operative cognitive deficits continue to exist, as significant cognitive impairments are 
reported up to 4 years after surgery (2-11). However, pre-operative cognitive functioning is often 
not examined, thereby limiting statements about changes in cognitive performance over time to 
date. The few studies that explored changes over time (following a pre-operative assessment, up 
to 9 months after surgery) predominantly demonstrated improved cognitive performance (6-10, 
12, 13). Yet, study results were presented on the group instead of individual patient level, fairly 
simple measures of change in performance were adopted (e.g., raw difference scores), and practice 
effects of repeated assessments were often not corrected for (14). 
Despite the fact that extensive cognitive deficits in meningioma patients have been described 
in a number of studies, research into predictors of cognitive performance in these patients remains 
limited (2). Mixed findings were reported with respect to the association between cognitive 
performance and, amongst others, tumor location and psychological factors (i.e., anxiety and 
depression) (2, 3, 5, 13, 1 5). Moreover, pre-operative predictors of late cognitive performance 
have only minimally been addressed in meningioma patients, which is remarkable given the 
negative impact of cognitive deficits on, for example, returning to social and professional activities 
after meningioma surgery (5, 16, 17). Information on the sociodemographic, clinical, psychological 
or cognitive characteristics of patients who are at risk for cognitive impairment on the long-term 
after surgery may help to inform patients and clinicians at an earlier stage. 
We explored cognitive functioning using a computerized neuropsychological battery in a 
large sample of meningioma patients before, and 3 and 12 months after surgery. Changes in 
performance were assessed at the group level as well as at the individual level using reliable 
change indices (RCIs) for each of the 2 time intervals. Additionally, we sought to identify pre-
operative predictors of late (i.e., 12 months post-operative) cognitive performance.
MATERIALS AND METHODS
Design 
The present study was part of a prospective longitudinal study in which brain tumor 
patients admitted for surgical resection between November 2010 and June 2017 underwent 
neuropsychological assessment (NPA) 1 day before surgery (T0) and 3 months after surgery (T3) 
as part of standard clinical neuro-oncological care. A (approximately) 12 months post-operative 
follow-up assessment (T12) was added as from January 2014 for research purposes in order to 
explore long-term cognitive functioning. 
Patients
Cases eligible for the current study were patients who underwent initial surgical resection, and who 
were, based on tissue obtained during surgery, histopathologically diagnosed with a WHO grade 
I or II meningioma. We excluded patients under the age of 18 years, with a history of intracranial 
neurosurgery, with intraosseous meningioma, with a recent history (≤ 2 years) of severe psychiatric 
or neurologic disorders, other major medical illnesses in the past year prior to surgery (e.g., 
cancer), a lack of basic proficiency in Dutch, or/and with the inability to undergo the NPA due to 
severe visual, motor, or cognitive problems. In addition, patients who participated in the cognitive 
rehabilitation studies that were simultaneously running at the Elisabeth-TweeSteden hospital were 
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excluded from the current study if they had been randomly assigned to the intervention (i.e., 
rehabilitation) group (18, 19). The cutoff for the time-interval between T0 and T12 assessment 
was set at a maximum of 21 months.  
All patients provided written informed consent. The study was approved by the Medical Ethics 
Committee (file number NL41351.008.12). The patient sample of the current study includes 68 
patients that were also included in a previous study (9, 20). 
Measures and procedure 
Sociodemographic characteristics. Patients were assessed per standardized protocol at all 3 time-
points, including a checklist and standardized interview at T0 (i.e., for obtaining and verifying 
sociodemographic information such as age, sex, and educational level). The highest completed 
level of education was classified according the Verhage scale (21). Its 7 categories were merged 
into 3 categories: low educational level (Verhage 1 until 4), middle educational level (Verhage 5), 
and high educational level (Verhage 6, 7). 
Clinical characteristics. Clinical information (e.g., data on medication use) was obtained from 
the electronic medical charts. A histopathological diagnosis was provided following surgery 
and categorized as WHO grade I meningioma or WHO grade II meningioma (22). By means of a 
pre-operative contrast-enhanced T1 weighted Magnetic Resonance Image tumor location, i.e., 
supratentorial versus infratentorial, and further classified as frontal (i.e., frontal, frontal-temporal, 
and frontal-parietal) versus non-frontal involvement, lesion side (i.e., right, left, bilateral), and the 
number of tumors were identified. In addition, total tumor volume (in mm3, of the meningioma 
which was operated on) was determined using semi-automatic segmentations performed in 
ITK-snap (23), followed by minor manual adjustments to lesion margins. The American Society 
of Anesthesiologist (ASA) score was considered as a physical status classification, ranging from 
ASA I (patient completely healthy) to ASA V (moribund patient) (24). ASA score was considered 
dichotomous: patients within ASA categories I and II were considered healthy, whereas patients 
within category III and IV were considered as patients with substantial comorbidities. Medication 
use was classified as the use of anti-epileptic drugs and/or corticosteroids. 
Psychological characteristics. Anxiety and depression were assessed using the Dutch translation of 
the Hospital Anxiety and Depression Scale (HADS) (25, 26). This self-report screening instrument 
consists of 14-items: each subscale (i.e., anxiety and depression) includes 7 items with response 
options ranging from 0-3, resulting in a score from 0-21 for each subscale, with higher scores 
representing more anxiety/depression symptoms. The Dutch translation of the HADS has good 
psychometric qualities, with Cronbach’s alphas of .81-.84 and .71-.86 for the anxiety and depression 
subscales respectively (26).  
Cognitive performance. The formal Dutch translation of the computerized neuropsychological 
battery CNS VS was used to examine cognitive performance. CNS VS comprises 7 neuropsychological 
tests, yielding measures of performance in 11 cognitive domains (27). Since the measures of 
performance in some domains are largely based on scores on the same tests, we only consider 
the following 7 cognitive domains in the current study: verbal memory, visual memory, processing 
speed, psychomotor speed, reaction time, complex attention, and cognitive flexibility. The NPA’s 
were performed using the CNS VSX local software app, on a laptop running a 64-bit operating 




After completing the battery, which takes approximately 30 - 40 minutes, raw scores for each 
cognitive domain amongst others are automatically provided by the program. Since effects of 
age, education, and sex were demonstrated on CNS VS performance in a Dutch normative sample 
(N =  158; age ranging from 20 to 80, education ranging from 10 to 26 years, assessed using CNS 
VS at baseline, and 3- and 12-months follow-up), raw cognitive domain scores were converted 
into sociodemographically-adjusted Z-scores (see Rijnen et al. (28) for a detailed description). In 
addition, effects of practice were found in the Dutch normative sample between the baseline and 
3-month follow-up assessment. Test scores at T3 and T12 were therefore corrected for practice 
effects, in addition to the sociodemographic corrections (29).
Statistical analyses
Patients’ characteristics. Descriptive and comparative analyses (i.e., one sample Z-tests and 
Chi-square tests of independence) were performed to explore potential differences in baseline 
sociodemographic, clinical, and psychological variables of the different patient samples assessed 
at T0, T3, and T12. 
Pre- and post-operative cognitive performance. Cognitive performance in individual patients was 
defined as impaired if the Z-score was  ≤ -1.50 (30). The numbers and percentages of patients 
scoring impaired were calculated for each cognitive domain at all time-points. In addition, a Chi-
square test of independence was conducted to compare the proportion of meningioma patients 
with impaired performance (per domain, per time-point) to the proportion of participants in 
the normative sample with deviant performance (i.e., to test whether deviant scores occurred 
significantly more frequently in meningioma patients than in controls). 
To explore mean performance on the 7 CNS VS cognitive domains of meningioma patients 
as compared to the normative controls at T0, T3, and T12, one-tailed one-sample Z-tests were 
performed (test values: mean (M) z = 0, standard deviation (SD) = 1). The mean Z-score for each 
cognitive domain (i.e., the difference between the patient sample and the normative sample in 
terms of SDs) equals Cohen’s d effect size (ES) when calculated according the following formula: 
Meanpatients-Meancontrols/SDcontrols. Therefore, mean Z-scores were considered as ES, with ES ≤ .50, 
between .51 and .79, and ≥ .80 respectively reflecting small, medium, and large effects (31).  
Changes in individual and group cognitive performance over time. Changes in cognitive performance 
over time in individual patients were examined using RCIs. RCIs illustrate changes in performance 
in individual patients, compared to changes in performance of controls, which prevents us from 
overlooking individual changes that are masked when considering changes at the group level. 
RCIs also allow corrections for methodological phenomena such as practice effects and imperfect 
test-retest reliabilities. A standardized regression-based RCI as described by Maassen, Bossema, 
and Brand (32) was adopted. Rijnen and colleagues (29) described details with regard to the RCI 
for changes in CNS VS performance specifically, based upon results on repeated testing in a Dutch 
normative sample from baseline (N = 158) to 3- (N = 133) and 12-month (N = 77) follow up. In the 
current study, change was defined as RCI values exceeding ±1.645 (corresponding with a two-tailed 
alpha of .10%, 90% confidence interval), with positive values indicating improved performance 
and negative values representing declines. The numbers of patients with improved, stable, and 
declined performance were counted for each cognitive domain at the 2 time intervals. Additionally, 
Chi-square tests of independence were conducted for the separate cognitive domains to compare 
the proportion ‘changers’ (improvers or decliners) in the meningioma patients to the proportion 
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‘changers’ in the normative sample (i.e., again to test whether changes occurred significantly more 
frequently in patients than in controls). In case of significance, standardized residuals were used 
to interpret Chi-square tables as to which cells (i.e., which change category: improved, stable, 
declined) contributed to the significant result. 
Changes over time (i.e., between T0-T3 and T3-T12) on the mean group level were assessed 
using the linear mixed effects models (LMEMs) that were fitted in order to identify pre-operative 
predictors of cognitive functioning (described in detail below) at T12. 
Predictors of late cognitive impairment. LMEMs for repeated measurements were fitted to 
examine pre-operative predictors of late (T12) cognitive functioning in meningioma patients for 
each cognitive domain. To estimate the model parameters, the restricted maximum likelihood 
estimate method was used. The Aikaike Information Criterion and Bayesian Information Criterion 
were used to estimate model fit. A heterogeneous first-order autoregressive covariance structure 
was selected, the random effect was subject-ID, and predictors were entered as fixed effects 
into the model. Outcome measures were the Z-scores for the separate cognitive domains of CNS 
VS at T12. Predictors included measurement (i.e., T0, T3, T12), sociodemographic (i.e., age, sex, 
educational level), and clinical (i.e., tumor location: hemisphere, supra- versus infratentorial, 
frontal versus non-frontal, number of meningioma, tumor volume, ASA score, medication use), and 
psychological (i.e., HADS anxiety and depression) variables. In addition, T0 scores of all domains 
were included into the LMEMS as cognitive predictors except the T0 scores of the predicted 
domain itself. Including T0 performance of a specific domain itself as a predictor (in addition to 
the inclusion of T0 performance by assessing the fixed effect of measurement) as well, would 
result in the factor being incorporated twice in the model. A variance inflation factor of over 10 
was used as cutoff for multicollinearity in the final models (33). 
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
version 24.0, except for the construction of the LMEMs for which we used the nmle (34) package 
in R (35). To reduce false discovery rate due to multiple testing, p-values were set against a 
corrected alpha, using the Benjamini-Hochberg (BH) procedure (leaving much greater power than 
the Bonferroni technique) (36, 37).  When performing the BH-procedure, individual p-values (i.e., 
per hypothesis) were put in order from smallest to largest: the smallest p-value has the rank of i 
= 1, the next smallest has i = 2, etc. Adjusted p-values were calculated by multiplying the original 
p-value by (m/i), where m is the total number of tests for that hypothesis, and i the rank of the 
specific p-value. BH-adjusted p-values are then compared to the original alpha level of .05, and 
the rank of the largest adjusted p-value that is smaller than .05 is used to calculate an adjusted 
alpha level by following the formula: (i/m)*.05 (36). 
RESULTS
Patients’ characteristics. Figure 1 shows the flow of meningioma patients through the current 
study. At T0, 261 patients were included. Thirty-two patients (12%) did not complete T3, resulting 
in 229 patients with a T0 and T3 assessment. Sixty-four percent of these patients did not undergo 
T12, mainly (i.e., in 33% of the patients) due to the later implementation of the long-term 
measurement. Eventually, 82 patients underwent a T0, T3, and T12 NPA. The median time interval 
between T0 and T3 was 2.83 months (ranging from 1.00 to 5.75 months). Median time interval 
between T0 and T12 was 12.42 months (ranging from 8.51 to 20.40 months).  
Table 1 presents sociodemographic, clinical, and psychological characteristics of the 




T0, T3, and T12 samples regarding sociodemographic, clinical, and psychological characteristics 
(p-values > BH-corrected alpha .002).
Figure 1 Flowchart of meningioma patients eligible for inclusion and follow-up
Pre- and post-operative cognitive performance. Prior to surgery, percentages of impaired patients 
ranged from 20.4% to 42.2% over domains (Figure 2). At T3 and T12 the percentages of patients 
scoring impaired on the cognitive domains respectively ranged from 16.7% to 32.6% and 13.8% 
to 22.5%. For 6 out of 7 domains at T0 and T3, and still 3 out of 7 domains at T12 after surgery, 
impairments were significantly more common in meningioma patients than in normative controls 
(ps < BH-corrected alpha of .04; Figure 2).  
We found significantly lower mean performance in meningioma patients as compared to 
the normative sample on all cognitive domains at T0 (ES ranging from -0.54 to -1.53), T3 (ES 
ranging from -0.37 to -1.22), and T12 (ES -0.35 to -0.76) (ps < BH-corrected alpha of .05; Table 
2). At T0 and T3, lowest mean Z-scores were found for complex attention (respectively -1.43 and 
-1.22) and reaction time (respectively -1.53 and -1.22). At T12, lowest mean scores were found for 
psychomotor Speed (-0.76), and again, reaction time (-0.65). 
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Table 1 Baseline sociodemographic, clinical, and psychological characteristics of samples of meningioma 
patients at each time-point
Baseline characteristics T0 (N = 261) T3 ( N = 229) T12 ( N = 82)
Sociodemographic characteristics
Age (years): mean ± SD (range) 57.8 ± 11.7 (23-82) 57.1 ± 11.7 (23-82) 55.9 ± 10.7 (32-75)
Education (years): mean ± SD (range) 13.7 ± 3.7 (6-26) 14.0 ± 3.7 (6-26) 14.4 ± 3.7 (8-26)
Sex: female/male N (%) 189(72) / 72(28) 167(73) / 62(27) 59(72) / 23(28)
Clinical characteristics 
WHO grade: I/II N (%) 240(92) / 21(8) 211(92) / 18(8) 76(93) / 6(7)
Number of meningioma: 1/≥2 N (%) 244(94) / 17(6) 217(95) / 12(5) 79(96) / 3(4)
Hemisphere: Left/right/bilateral N (%) 106(41) / 124(48) / 31(11) 94(41) / 107(47) / 28(12) 32(39) / 39(48) / 11(13)
Supratentorial/infratentorial N (%) 238(91) / 23(9) 208(91) / 21(9) 75(91) / 7(9)
Frontal/non-frontal N (%) 154(59) / 107(41) 135(59) / 94(41) 46(56) / 36(44)
Tumor volume (cm3): median (range) a 33.5 (0.45-150.22) 32.0 (0.45-150.22) 34.5 (0.45-144.8)
ASA score: I,II/III,IV N (%) 225(86) / 36(14) 202(88) / 27(12) 71(87) / 11(13)
Use of medication: yes/no N (%) b  114(45) / 139(55) 100(44) / 123(54) 36(45) / 44(55)
Psychological characteristics 
Anxiety HADS: mean ± SD (range) c 7.2 ± 4.2 (0-20) 7.0 ± 4.2 (0-19) 7.0 ± 4.0 (0-17)
Depression HADS: mean ± SD (range) c 5.9 ± 4.6 (0-21) 5.7 ± 4.5 (0-21) 6.0 ± 4.9 (0-21)
WHO World Health Organization (20); ASA American Society of Anesthesiologists (21); AED antiepileptic 
drug; HADS Hospital Anxiety and Depression Scale (23)  
a data missing T0 N = 30; T3 N = 24; T12 N = 6; 
b data missing T0 N = 8; T3 N = 6; 
c data missing T0 N = 32; 
T3 N = 25; T12 N = 7 
Table 2 Cognitive performance on CNS VS domains of meningioma patients compared to the 
normative sample
T0 T3 T12
Domain Z-score a M(SD) Z-test Z-score 
a M(SD) Z-test Z-score a M(SD) Z-test
Verbal Memory -0.67(1.30) -10.38* -0.90(1.35) -13.50* -0.59(1.19) -5.29*
Visual Memory -0.54(1.23) -8.35* -0.37(1.26) -5.52* -0.35(1.14) -3.09*
Processing Speed -1.11(1.36) -17.39* -0.85(1.22) -12.75* -0.58(0.99) -5.22*
Psychomotor Speed -1.31(1.66) -20.45* -0.93(1.36) -13.95* -0.76(1.14) -6.72*
Reaction Time -1.53(2.38) -23.79* -1.19(2.02) -17.83* -0.65(1.61) -5.81*
Complex Attention -1.43(2.60) -21.61* -1.22(2.29) -18.06* -0.61(1.92) -5.43*
Cognitive Flexibility -1.34(2.28) -20.69* -1.12(1.79) -16.62* -0.48(1.46) -4.34*
* p < BH-corrected alpha .05
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Changes in individual and group cognitive performance over time. On the individual level, patients 
demonstrated improvements more often (ranging from 8% to 28% between T0-T3 and 3% to 
30% between T3-T12 over different cognitive domains) than declines (ranging from 3% to 15% 
between T0-T3 and 1% to 15% between T3-T12) over time (Table 3). To compare, 5% to 6% of 
the normative sample showed declined performance, and another 5% to 6% showed improved 
performance over time (i.e., RCI values exceeding ±1.645). Declined performance in patients was 
for none of the cognitive domains, neither over the first (T0-T3) nor over the second (T3-T12) 
interval, significantly more frequent than in the normative sample, except for declines on reaction 
time between T0-T3 (χ2 (2) = 26.84, p = <.001), and T3-T12 (χ2 (2) = 28.45, p = <.001). However, 
improvement of performance occurred significantly more frequently on 6 out of 7 domains over 
the first interval (i.e., all domains but verbal memory), and 4 out of 7 domains (i.e., verbal memory, 
reaction time, complex attention, and cognitive flexibility) over the second interval. 















Verbal Memory 16 (8%) 175 (84%) 17 (8%) 1 (1%) 61 (78%) 16 (21%)*
Visual Memory 11 (5%) 168 (81%) 29 (14%)* 6 (7%) 69 (90%) 2 (3%)
Processing Speed 6 (3%) 167 (78%) 40 (19%)* 2 (3%) 71 (92%) 4 (5%)
Psychomotor Speed 13 (6%) 142 (66%) 60 (28%)* 6 (8%) 66 (87%) 4 (5%)
Reaction Time 31 (15%)* 132 (62%) 49 (23%)* 12 (15%)* 44 (56%) 23 (29%)*
Complex Attention 24 (11%) 142 (69%) 41 (20%)* 7 (9%) 51 (64%) 21 (27%)*
Cognitive Flexibility 23 (11%) 140 (67%) 45 (22%)* 4 (5%) 51 (65%) 24 (30%)*
* p < BH-corrected alpha .04, compared to proportions of reliable decline, stability and improvement in 
the normative sample 
The final LMEMs demonstrated changes in cognitive performance on the group level, as shown 
in Table 4. Patients’ performance improved significantly over the first time interval on 3 domains. 
Performance on verbal memory was found to decline significantly (B = -0.22, SE = 0.09, p = .018), 
and no significant changes in performance were found for visual memory, complex attention, 
and cognitive flexibility (respectively B = 0.19, SE 0.09,  p = .038; B = 0.25, SE = 0.15, p = .095; and 
B = 0.21, SE = 0.12, p = .079). Over the second interval, significantly improved performance was 
found for 4 out of 7 domains, no changes were found between T3 and T12 on verbal memory (B 
= 0.26, SE = 0.13, p = .044), visual memory (B = -0.10, SE = 0.12, p = .398), and psychomotor speed 
(B = 0.02, SE = 0.09, p = .864). The variability in time between T0 and T12 (i.e., ranging from 8 to 
20 months) did not significantly affect late cognitive performance on any of the CNS VS domains 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Predictors of late cognitive impairment. Table 4 shows the final LMEMs for the cognitive domains 
of CNS VS. Older age, and cognitive flexibility score at T0 was significantly associated with a lower 
Z-score on complex attention at T12. Male sex and higher T0 psychomotor speed performance 
were significantly predictive for a higher score on processing speed. A high educational level and 
better T0 processing speed performance significantly predicted a higher psychomotor speed score. 
Higher T0 verbal memory performance significantly predicted a higher visual memory score, and 
vice versa, higher T0 visual memory performance predicted a higher verbal memory Z-score. 
Higher performance on reaction time and complex attention at T0 were significantly predictive of 
higher cognitive flexibility scores (p’s < BH-corrected alpha of .005). None of the pre-operatively 
known clinical or psychological variables were found to significantly predict cognitive performance 
at T12 (p’s > BH-corrected alpha of .005). 
The former is also reflected by the large proportion of variance explained (i.e., marginal R2) by 
the cognitive T0 predictors for the LMEMs. The variance explained ranged from 3% to 14% when 
only sociodemographic variables were included in the LMEMs as fixed effects, from 5% to 22% 
when clinical variables were added, from 7% to 22% when psychological variables were added, 
and from 24% up to 85% when the cognitive variables were added to the models (data not shown). 
DISCUSSION
In general, pre-operative cognitive deficits have been documented in patients with meningioma, 
and a number of studies suggested that patients also show post-operative impairments (2-11). 
Prospective studies including pre-operative assessments, also including analyses on the individual 
level, however, are still often lacking. 
We found extensive pre- as well as 3- and 12-months post-operative cognitive deficits in 
our large sample of meningioma patients: mean performance of patients was significantly 
lower on all cognitive domains at all 3 time-points as compared to the normative sample with 
predominantly large, but also medium, effect sizes (Cohen’s d ranging from .35 up to 1.53). On the 
individual patient level, impairments were significantly more common in meningioma patients 
on respectively 6 out of 7 cognitive domains at T0 and T3, and 3 out of 7 domains at T12 when 
compared to normative controls. Performance on psychomotor speed, reaction time, and complex 
attention was most frequently, as well as most severely, impaired. 
The results indicate that cognitive performance improves on the group level over time. Over 
the first time interval we found significantly improved scores for processing speed, psychomotor 
speed, and reaction time. Further improved performance was found for processing speed, reaction 
time, complex attention, and cognitive flexibility over the second time interval. Yet, as it is expected 
that some patients show improved, and other patients show declined performance over time, 
mean results of a group may mask changes in performance in individual patients. RCIs showed 
respectively declined and improved performance in 1 to 15% and 3 to 30% of the patients over the 
different cognitive domains over the 2 time intervals. However, the proportions of patients with 
declined performance was for none of the domains, and for none of the 2 intervals significantly 
larger than in the normative sample, except for declines on reaction time over both intervals 
(15% of the patients declining between T0-T3, and again 15% between T3-T12). In contrast, 
improvements were significantly more common in meningioma patients (as compared to the 
normative sample) for most cognitive domains over the first time interval, and over half of the 
cognitive domains over the second time interval. Improvements of performance over time were 
the most frequent and largest for the domains that were most frequently and severely impaired 
at pre-operative assessment, namely reaction time, psychomotor speed, and complex attention. 
85
INDIVIDUAL CHANGES AND PREDICTORS OF LATE COGNITIVE FUNCTIONING
It should be noted that post-operative improvements do not imply that performance of patients 
returns to unimpaired levels: group performance was still significantly lower on all domains as 
compared to the normative sample, and in addition, about 13% up to almost a quarter of the 
patients showed impaired performance over different domains at T12. 
The LMEMs, conducted in order to identify pre-operative predictors of late cognitive 
performance, indicated younger age, male sex, and a higher education as predictors of better 
performance on some domains 12 months after surgery, while sociodemographically corrected 
Z-scores (28) were used. These findings can be partly related to the concept of cognitive reserve 
that posits cognitive processes, consisting of differences in cognitive efficiency, capacity or 
flexibility that are shaped by for example education, socioeconomic status and life experiences, 
as explanation of differences between patients who are functionally impaired and patients who 
are not despite equal brain pathologies (38-41). The finding of additional predictive effects of 
age and education, factors that are both associated with cognitive reserve (41, 42), suggest that 
these variables play a larger role in meningioma patients than in healthy controls. Neither the 
clinical nor the psychological variables appeared to have significant predictive value for late 
cognitive performance. Mixed results have been demonstrated in previous studies with regard 
to the location and volume of meningioma in relation to cognitive performance; whereas some 
studies demonstrated no significant effects (2), others demonstrated for example more deficits in 
patients with frontal meningioma or with a relatively large tumor volume (12, 13 , 15 ,20). However, 
meningioma do not directly damage brain regions but may reduce the functional integrity even 
of remote brain regions through compression by the tumor (43). Therefore, long-term cognitive 
deficits are not likely locally-based and consequently, not expected to be pre-operatively 
predictable by tumor location or volume. Results of the current study also suggest that pre-
operative mood (i.e., anxiety and depression) is not a predictor for cognitive outcome. Yet, some 
(small) associations between mood and cognitive performance after surgery were demonstrated 
before (9). A pre-operative increase of anxiety and depression can be a very normal reaction to 
the diagnosis and upcoming major treatment of a meningioma, however, it is not very likely that 
this increase is also related to late cognitive deficits. 
As mentioned previously, the current study has a larger sample size and a longer follow-up (i.e., 
12 months versus 3 months) as compared to our previous study (N = 68) (8). CNS VS was assumed 
to be suitable for serial administration without inducing practice effects at the time of our previous 
study (9, 27). However, we demonstrated effects of sex and education on CNS VS performance 
in addition to the known effects of age in the Dutch normative sample, as well as practice effects 
over repeated assessments (28, 29). It should be noted that the observed severity of cognitive 
deficits of meningioma patients in our previous study was therefore possibly underestimated, in 
particular with respect to cognitive flexibility. In addition, improvement due to practice effects may 
have overwhelmed effects of ‘true’ change over time, and may have contributed to the observed 
improvement in test performance in the former patient group, mainly on cognitive flexibility and 
processing speed (9). 
The current study has some limitations that should be noted. We solely included patients 
who were considered acceptable candidates for surgery and capable of undergoing the pre-
operative NPA. Consequently, results may be biased towards an overestimation of cognitive 
performance in meningioma patients in general. Also, one should take into account that the T12 
assessment was (opposed to T0 and T3) no longer part of clinical neuro-oncological care. As this 
assessment was implemented about 4 years after the start of the study, a significant proportion 




since surgery for these patients. A considerably smaller number of patients (21%) dropped-out 
because they were not motivated to participate. Comparisons of baseline characteristics of the 
samples included at T0, T3, and T12 suggest that there were no sociodemographic, clinical, and 
psychological differences between patients who completed the T12 assessment and those who did 
not. It is therefore unlikely that only a specific group of highly motivated, relatively well-functioning 
patients was willing to participate in this follow up.    
Increasing attention is being paid to rehabilitation in meningioma patients. Recently, positive 
effects of a 12-week exercise program were suggested on amongst others symptoms of depression 
and verbal learning in a small group of meningioma patients, although there was no control 
for practice effects in this study (44). Another study presented positive effects of cognitive 
rehabilitation in the acute post-operative phase (starting within 1 week after hospital admission) 
on cognitive performance in neuro-oncological patients (45). Feasibility of and patient satisfaction 
with an iPad-based cognitive rehabilitation program was recently demonstrated in a small and 
heterogeneous group of patients with glioma and meningioma (18). A randomized controlled 
trial on the effects of this program on, amongst others, cognitive performance in a larger sample 
is currently ongoing (19). The increasing opportunities for rehabilitation of cognitive functions 
demand knowledge of characteristics of meningioma patients who are at high risk of cognitive 
deficits after surgery, as presented by the current study.
Although performance improves over time on the group level in our large sample of 
meningioma patients, the majority of individual patients showed stable cognitive functioning, 
and cognitive scores still remain significantly lower than in healthy controls up to 12 months 
after surgery. Our study demonstrates that a pre-operative NPA, together with easily available 
sociodemographic information, may provide valuable information on the late cognitive outcome 
of individual meningioma patients. This knowledge can help to inform patients and clinicians on 
late cognitive status at an early stage. In addition, it emphasizes the need for pre-surgical NPA in 
meningioma patients, and stresses the need for timely rehabilitation in patients who are at risk 
for cognitive impairment. 
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Meningiomas, the most common primary CNS  tumors, are in the vast majority of cases benign 
tumors with a good prognosis. Despite abundant medical reports about surgical techniques, clinical 
outcome, and long-term survival, relatively little is known about the impact of surgery or other 
treatments on the course of cognitive functioning over time. Most meningiomas are benign and 
characterized by slow growth. Many of them remain asymptomatic for a patient’s lifetime, or are 
only discovered incidentally by brain imaging (1). Part of the meningiomas become symptomatic. 
They may have grown to a considerable size before clinical symptoms appear, presumably due to 
slow growth and the plastic potential of the brain (2-4). Cognitive deficits can be very subtle and 
easily go undetected up on routine clinical examination. The aim of this thesis was to evaluate 
cognitive dysfunction in more detail in meningioma patients, and, more specifically to gain new 
insights in individual performance, change, and predictors of cognitive performance in meningioma 
patients before and after surgery. In addition, this thesis also aimed to evaluate computerized 
testing as a clinical instrument to detect cognitive impairment in meningioma patients. 
A systematic review (Chapter 2) was done to evaluate the available data and the quality of 
studies on cognitive impairment in meningioma patients before and after treatment (i.e., surgery 
with or without adjuvant radiotherapy). Study methods used to evaluate cognitive function in 
meningioma patients were also reviewed. It was observed that surprisingly few studies (11 
publications) had been conducted at that time (2015) on cognitive functioning in meningioma 
patients. In addition, drawing conclusions from these studies and comparison of results between 
them was complicated by several methodological limitations, such as a lack of pre-treatment 
assessments, variations in the number and types of neuropsychological tests used, different 
definitions of cognitive impairment, low quality of normative data, and absence of control for 
practice effects (i.e., improvements in performance due to familiarity with the test, its items, and 
test procedures as opposed to true cognitive improvement). Despite these limitations, the results 
from the studies reviewed suggest that most of meningioma patients are faced with cognitive 
deficits in several cognitive domains before surgery. In general, most commonly affected domains 
were memory, attention, and executive function. Following surgery, most of these patients seem to 
improve in cognitive functioning, mostly on memory, attention, and executive function. However, 
they were still left with impairments in a wide range of cognitive functions compared to healthy 
controls, whereby there is a lack of consistency across studies about the domains that did or 
did not improve after surgery. A survey of the literature thus indicated that the prevalence of 
cognitive impairments in meningioma patients is much larger than usually acknowledged on clinical 
grounds (5). This stresses the relevance of this research project and the need to evaluate cognitive 
functioning in meningioma patients more thoroughly. 
In recent years various computerized neuropsychological test batteries such as CNS VS 
have been developed that offer an attractive alternative to (often more lengthy) traditional 
neuropsychological paper-based assessment. Normed scores are automatically generated by 
CNS VS and represent the performance of an individual relative to the American normative sample 
controlled for age. We evaluated the first-time use of the formal Dutch translation of the CNS 
VS battery as computerized clinical neuropsychological screening tool for cognitive function 
in a (Dutch) neurological patient population (N = 32). Cognitive performance on CNS VS was 
examined in patients with trigeminal neuralgia (TN) before microvascular decompression (MVD) 
in comparison with healthy controls. Since the largest neurocenter of the Netherlands is located 
in the Elisabeth-TweeSteden Hospital, we had access to a relatively large group of these patients. 
In addition, no information was available on cognitive performance in TN patients as no prior 
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studies had been conducted, which prompted us to start our research project with this particular 
patient group. Our pilot study showed that patients with TN scored significantly lower than the 
American normative sample on 5 out of 5 selected cognitive domains (i.e., composite memory, 
psychomotor speed, reaction time, complex attention, and cognitive flexibility). Comparisons 
between patients and a small control group of Dutch subjects (N = 20) tested with the same 
battery revealed quite the same pattern of differences in mean test performance. We concluded 
that a brief computerized neuropsychological assessment can be a practical alternative for lengthy 
traditional neuropsychological testing in the clinical research setting, and that patients with TN 
need to be carefully evaluated for cognitive deficits (Chapter 3). 
The major aim of this research project was to evaluate cognitive function in meningioma 
patients with computerized tests. Data from 68 meningioma patients was collected in a 
prospective study in which patients were neuropsychologically tested before and 3 months after 
surgery. In line with previous studies with conventional (i.e., paper and pencil) neuropsychological 
tests, meningioma patients demonstrated significantly lower scores on all 7 cognitive domains 
(i.e., memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, 
processing speed, and executive functioning) before surgery. After surgery we observed significant 
improvements on 5 out of 7 domains at group level (i.e., memory, complex attention, cognitive 
flexibility, processing speed, and executive functioning). For psychomotor speed and reaction 
time, no significant improvement was observed. As psychomotor speed and reaction time were 
less impaired than other cognitive domains at baseline (i.e., before surgery), this may have left less 
room for improvement. However, group performance was still significantly lower on all domains as 
compared to the American normative sample. At the individual level, we found that respectively 
69% and 44% of the patients scored lower than 1.5 SD below the mean of the American normative 
sample on at least 1 cognitive domain pre- and post-operatively. As no 2 presentations of CNS VS 
are similar due to the random presentation of stimuli, the battery was assumed to be suitable for 
serial administration without inducing practice effect (6). Therefore, there seemed to be no need 
to correct for practice effects. Our study again suggested that a rapid, efficient and cost-effective 
computerized neuropsychological test battery is a good alternative for conventional, lengthy 
neuropsychological testing (Chapter 4).
As CNS VS’ normative data collected in an American population were established over a decade 
ago, with corrections for age only, the applicability of the original CNS norms and effects of other 
sociodemographic variables on cognitive performance was examined in a healthy Dutch sample 
(N = 158). The Dutch sample showed better performance on CNS VS as compared to that of the 
American normative sample on the 2 domains covering different types of speed (psychomotor 
speed and processing speed) as well as on cognitive flexibility. In addition, effects of education and 
sex on CNS VS performance were identified in the Dutch sample and should therefore be taken 
into account when cognitive performance is evaluated in individual patients. Based on these data, 
we established regression-based normative formulae to adjust for the effect of sociodemographic 
variables on performance on CNS VS. In future evaluations of performance in our (Dutch) patient 
studies, and also in clinical practice at the Elisabeth-TweeSteden Hospital, these normative data 
will be used instead of the American norms (Chapter 5). Below we will discuss the implications of 
these findings for the results described in Chapter 4. 
Final analyses (Chapter 6) were conducted to investigate individual changes in cognitive 
performance over time and predictors of late cognitive functioning in meningioma patients after 
surgery. This study has a larger sample size and a longer follow-up (i.e., 12 months versus 3 




261 patients were assessed, and 229 and 82 patients were retested 3 and 12 months after surgery 
respectively. In accordance with are previous study (N = 68; Chapter 4) we found significantly lower 
performance in patients on all (7 out of 7) cognitive domains at all 3 time-points as compared to 
our Dutch normative sample (N = 158). Although cognitive performance improved at the group 
level, the majority of individual patients showed stable cognitive functioning over time. In addition, 
group performance was still significantly lower on all domains as compared to the normative 
sample. Unlike in our previous study, we corrected for practice effects since we applied Reliable 
Change Index (RCI) formulae for the determination of reliable change in CNS VS’ domain scores, 
based upon results on repeated assessments of CNS VS in the same Dutch normative sample as 
described above (N = 158, N = 131, N = 77 at baseline, at 3-months and 12-months follow-up) 
(6). The implications of these correction for practice effects for the results described in Chapter 
4 will be discussed below. In addition, we found that pre-operative performance predicted late 
cognitive performance, and that lower age, male sex, and higher educational level were found to 
predict better cognitive performance 12 months after surgery. These results can help to inform 
patients and clinicians on late cognitive status at an early stage, and emphasize the need for 
cognitive rehabilitation when necessary. Patients whose cognitive performance is already impaired 
before surgery are at risk of having late cognitive deficits: this stresses the need for implementing 
(pre-operative) neuropsychological assessments into the clinical care of meningioma patients.
METHODOLOGICAL CONSIDERATIONS 
The findings of the studies described in this thesis need to be considered in the context of the 
methodological merits and limitations of this project.
 Although the studies in this thesis provide us with evidence to apply CNS VS as a brief 
computerized neuropsychological battery to evaluate cognitive function in patients with 
meningioma, some limitations concerning the use of CNS VS should be noted. The results from 
the pilot study in patients with TN (N = 32) at that time led us to use CNS VS’ normative database 
in our prospective study on the incidence and severity of cognitive dysfunction in meningioma 
patients before and 3 months after surgery (7) (Chapter 4). In this study, patients’ cognitive 
scores were comparable to the original American CNS VS norms. However, a possible Flynn effect 
should be considered given the headspring of the normative data presented by CNS VS (i.e., the 
original peer reviewed reliability and validity paper was published in 2006 (6)). The Flynn effect 
refers to a substantial rise of the population’s performance on tests of intelligence in developed 
countries, typically about 3 to 5 points per decade (i.e., on a IQ scale with a mean of 100 and 
standard deviation of 15 points) (8, 9). Since 2006, the normative database has been expanded 
to over 1,900 participants, but unfortunately no information on the updated CNS VS normative 
database has been reported to date. As a result, there is no publicly available description of the 
composition of the American sample regarding background characteristics, nor the basis on which 
participants were classified as “normal,” except that they had “no past or present neurological or 
psychiatric disorder, head injury, and learning disabilities” (10). Another limitation of the original 
CNS VS’ normative data concerns the absence of adjustments for effects of education and sex, 
as normalized scores are solely age-corrected. Age, education, and to a lesser extent sex have 
extensively been found to correlate with performance on numerous neuropsychological tests (11), 
including performance on computerized tests (12-14). As described in Chapter 5, we found that 
Dutch participants (N = 158) showed higher scores on 3 out of 7 cognitive domains (i.e., processing 
speed, psychomotor speed, cognitive flexibility) as compared to the American normative sample. 
In addition, effects of education and sex on CNS VS performance were also identified in the Dutch 
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sample (N = 158). Therefore, it should be noted that, as described in Chapter 4, the observed 
severity of cognitive deficits in our prospective study of meningioma patients (N = 68), was possibly 
underestimated in these patients, in particular with respect to cognitive flexibility. 
In addition, despite the fact that CNS VS is assumed to be suitable for repeated testing 
without inducing practice effects1 due to the random presentation of stimuli, there still could be a 
learning effect of the battery in general i.e., performance gain at retest due to familiarity with, and 
recognition of, test materials and procedures (16). In addition, our follow-up study on test-retest 
reliabilities and practice effects for CNS VS demonstrated that Dutch healthy participants scored 
significantly higher on the domains of cognitive flexibility, processing speed, and reaction time at 
the 3-month retest compared to the first assessment. No significant differences in performance 
were found between the second and third assessment (17). Consequently, improvement due 
to practice effects may have initially overwhelmed effects of change over time, and may have 
contributed to the observed improvement in test performance in our patient group (N = 68; 
Chapter 4) mainly on cognitive flexibility and processing speed, as described in Chapter 4. In 
addition, as described in Chapter 6, RCIs with correction for practice effects (in addition to the 
sociodemographic corrections (17)) demonstrated that the majority of individual patients (ranging 
from 62% to 84%) showed stable cognitive functioning over time. RCIs showed respectively 
declined and (more often) improved performance in 1 to 15% and 3 to 30% of the patients over 
the different cognitive domains. We conclude that the observed  improvements in our first patient 
study (N = 68; Chapter 4) merely reflect practice effects, in particular with respect to cognitive 
flexibility. 
Furthermore, we are aware that for some patients computerized testing is more difficult than 
for others, for example for older patients who are not familiar with computers (18). Iverson and 
colleagues (19) found that people with ‘frequent’ computer use performed better than people 
with ‘some’ computer use on tests requiring rapid visual scanning and keyboard work. It should 
be noted that computer skills - including keyboard work and on-screen visual scanning - have 
improved tremendously over the past decade, which may result in improvements in overall 
performance on computerized neuropsychological speed tests. As can be expected from the more 
frequent use of computers nowadays, our Dutch sample (N = 158) comprised too few participants 
with only some or none computer familiarity to look into these effects. The beneficial effects of 
computer familiarity may (partly) explain the differences between the American 2006 group and 
the Dutch 2016 group (20). 
With regard to the tests by CNS VS, a closer inspection shows that the verbal memory test 
(VBM) and the visual memory test (VIM) are actually recognition tests, not tests of recall (6). 
Since recognition is a response to a sensory cue and recall is the retrieval of information from 
memory without a cue, recognition can be expected to be easier than recall (21). As a result, we 
expect performance on recall tests to be more impaired in meningioma patients as compared 
to recognition tests, and even worse as compared to healthy participants. Therefore, patients’ 
performance on the memory domain may be underestimated in our studies.
1.  Practice effects are improvements in performance due to familiarity with the test, its items and test 




CNS VS’ cognitive domains show considerable overlap with other domains of the battery (i.e., 
composite memory, executive functioning, simple attention, and motor speed), and therefore we 
did not consider all 11 cognitive domains in our analyses. 
A note with regard to our selection of meningioma patients should be mentioned (Chapters 
4 and 6). Our sample mainly consisted of patients with a meningioma with a diameter > 3 cm, as 
our hospital tends to adopt a wait-and-scan approach in patients with a smaller meningioma or 
treat them with Gamma Knife radiosurgery (i.e., a very precise form of therapeutic radiotherapy 
as alternative to traditional brain surgery and whole brain radiation therapy). Performance in our 
study population may therefore be slightly worse than performance in the general population of 
symptomatic meningioma patients. On the other hand, patients with large tumors and patients 
who were unable to undergo the neuropsychological assessment due to severe visual, motor, or 
cognitive problems, were excluded from analyses. This selection bias may therefore have resulted 
in a better performance of this group of meningioma patients. 
Despite these given the methodological considerations and limitations of the studies presented 
in this thesis, this research project is unique in evaluating cognitive deficits in meningioma patients 
with a brief computerized test battery, in combination with the acquired insights in individual 
performance, change, and predictors of cognitive performance after surgery. The limited data 
available on the cognitive outcomes in these patients at the start of this project have emphasized 
the importance to thoroughly evaluate cognitive functioning in meningioma patients both in 
research and clinical practice. 
CLINICAL IMPLICATIONS AND SUGGESTIONS FOR FUTURE RESEARCH
The studies presented in this thesis provide evidence for cognitive deficits in patients with 
meningioma before and 3 months after surgery, both at group and individual patient level, which 
tend to persist during the first year after surgery. Improvements in cognitive performance were 
somewhat more common than declines, but only a relatively small number of meningioma patients 
showed changes from pre- to post-operative assessment. Pre-operative cognitive performance of 
meningioma patients turned out to be the most predictive variable for late cognitive performance, 
whereas sociodemographic, clinical, and psychological variables were not -or only to very limited 
degree- predictive for cognitive outcomes. Surgery generally had a beneficial effect on cognitive 
functioning. 
Anxiety and depression symptoms as emotional reactions to diagnosis and prognosis may also 
have a negative impact on cognitive functioning in meningioma patients (22). However, no clear 
relationship was found with respect to the psychological aspects of having a brain tumor and its 
influence on cognitive functioning. As described in Chapter 4, no statistically significant correlation 
between pre-operative anxiety and pre-operative cognitive functioning was found. On the other 
hand, there was a negative association of pre-operative depression with pre-operative cognitive 
function. Future research will help to better define the influence of preexisting depression with 
cognitive dysfunction after surgery. In addition, as described in Chapter 6, pre-operative anxiety 
and depression did not predict late cognitive outcome. A pre-operative increase of anxiety and 
depression can be a very normal reaction to the diagnosis and upcoming major treatment of 
meningiomas and may have affected pre-operative cognitive function. However, it is not likely 
that this increase is also related to late cognitive deficits. Surprisingly, neither the clinical nor 




Other variables such as ineffective coping strategies (e.g., denial or passive coping) of patients 
who experience stress related to their medical condition may put patients at risk for cognitive 
dysfunction. Differences in coping strategies may serve as an indirect explanation for the inter-
individual differences in cognitive performance that exist among meningioma patients. In patients 
with non-CNS cancers, coping was found to be a significant mediator of the relationship between 
stress and neuropsychological outcomes, confirming that active coping was one mechanism that 
linked cancer stress and (better) neuropsychological outcomes  (23-25). 
In addition, evidence also suggests that germline mutations and tumor genetic factors may 
affect (individual differences in) the development of cognitive impairment in primary brain tumor 
patients (26). Our research group is currently investigating the role of the apolipoprotein E (ApoE) 
ε4 allele in the explanation of individual differences in cognitive performance in a large sample 
of patients with meningioma and glioma.  In other populations, including traumatic brain injury 
and stroke, ApoE status is known to influence neurocognitive outcome (26). 
Based on the results of these studies, clinicians and patients can be better informed about 
cognitive dysfunction and should be aware of this risk in meningioma patients. As mild or moderate 
cognitive impairments are insufficiently detected with routine medical examinations, we propose 
that meningioma patients should be routinely evaluated with neuropsychological testing when 
they are admitted for brain surgery. For this purpose, a brief computerized neuropsychological 
assessment such as CNS VS (6) can be a practical alternative for traditional neuropsychological 
testing. Since CNS VS’ cognitive domains show considerable overlap with other domains of the 
battery, we suggest not to consider all 11 cognitive domains in  analyses. Diagnosis and treatment 
of these cognitive deficits are expected to improve outcomes and quality of life in meningioma 
patients by timely providing appropriate care (for example cognitive rehabilitation (27, 28)). 
As a spin-off of the current study new research questions regarding meningioma patients 
have developed since then, for example on the impact of cognitive deficits on work functioning, 
community integration and subjective cognitive complaints. Our group also explored the 
relationship between tumor location and cognitive functioning in meningioma patients (29). 
Also, an iPad-based cognitive rehabilitation program for our meningioma patients was developed 
(30). All these studies were established within the department of Neurosurgery of the Elisabeth-
TweeSteden Hospital (Tilburg, The Netherlands) together with department of Cognitive 
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